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1.1 Sustained Drug Delivery system 1,2 
 
 There has been 60 years of research and development experience in the 
sustained drug release area since the patent, and a number of strategies have been 
developed to prolong drug level in the body. With many drugs, the basic goal of 
therapy is to achieve a steady-state blood or tissue level that therapeutically effective 
and non-toxic for an extended period of  time.  
 
In the recent past, controlled release concept and technology have received 
increasing attention in the face of growing awareness to toxicity and ineffectiveness 
of drugs when administered or applied by conventional methods. Thus drugs applied 
in the form of tablets, capsules, injectables and ointments etc., usually produce wide 
range of fluctuations in drug concentration in the blood stream and tissues with 
consequent undesirable toxicity and poor efficiency. This factor as well such as 
repetitive dosing and unpredictable absorption led to the concept of controlled drug 
delivery systems or therapeutic systems3. A dosage form that one or more drugs 
continuously in a pred pattern for a fixed period of time, either systematically or to a 
specified target organ is a controlled drug delivery system. The event of drug delivery 
system brings rate controlled delivery with fewer side effects, increased efficacy and 
constant delivery. The primary objective of controlled drug delivery systems is to 
ensure safety of drugs as well as patient compliance. 
 
The goal of any drug delivery systems is to provide a therapeutic amount of 
drug to the proper site in the body to achieve promptly and then maintain the desired 
drug concentration. Two aspects are most important to drug delivery, namely spatial 
placement and temporal delivery of a drug4. Spatial placement related to targeting 
drug to a specific organ or tissue. While temporal delivery refers to controlling the 
rate of drug delivery to the target tissue. 
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1.1.2Requirements for sustained drug release4 
 
Design of sustained release products is normally a very difficult task because 
of interplay of the physical-chemical-biological properties of the drug, the patient 
disease state and technological limitations in fabrication of the final dosage form. 
Depending upon the drug, disease state, route of administration, but before a final 
decision is made to proceed with the dosage form; all these factors must be 
considered.   
 
1.1.3Advantages of Sustained Release Dosage Form5 
 
i. Frequency of drug administration is reduced. 
ii. The Patient compliance can be improved, and drug administration can be 
made more convenient. 
iii. blood level oscillation characteristic of multiple dosing of conventional 
dosage forms is reduced, because a more even blood level is maintained. 
iv. Implicit in the design of sustained release forms, is that the amount of drug 
administered can be reduced, thus maximizing availability with a minimum 
dose. 
v. The safety margin of high-potency drugs can be increased, and the incidence 
of both local and systemic adverse side effects can be reduced in sensitive 
patients. 
 
1.1.4 Disadvantages 
 
i. Administration of sustained release medication does not permit the prompt 
termination of therapy. 
ii. The physician has less flexibility in adjusting dosage regimens. This is fixed 
by the dosage form regimen. 
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iii. Sustained release forms are designed for the normal basis of average drug 
biologic half-lives. Consequently, disease states that alter drug disposition, 
significant patient variation, so forth are not accommodated. 
iv. Economically more costly processes and equipment are involved in 
manufacturing many sustained release forms. 
    
1.2. Hydrophilic Polymer Matrix System (HPMS) 
 
 Hydrophilic Polymer Matrix System (HPMS) are widely used in oral 
controlled drug delivery because they make it easier to a desirable drug-release 
profile, as they are cost effective and have abroad US FDA acceptance. It consists of 
hydrophilic polymer, drug and other excipients distributed throughout the matrix6.  
This dynamic system is dependent on polymer wetting, hydration and dissolution for 
controlled release of drug.  At the same time, other soluble excipients (or) drug 
substance will also wet, dissolve and diffuse out of the matrix, whereas insoluble 
excipients (or) drug substances will be  held in place until the surrounding polymer, 
excipients (or) drug complex erodes (or) dissolves away. 
 
           Matrix controlled release tablet are relatively simple system that are more 
forgiving of variations in ingredients, production methods and end-use conditions 
when compared to coated controlled release tablets of other systems.  This results in 
more uniform release profiles with a high resistance to drug dumping. Hydrophilic 
matrix systems are relatively easy to formulate with existing conventional equipments 
and processing method5. One goal of this study was to develop uncoated HPMC 
matrix tablet by wet granulation process, evaluating the relationship and influence of 
excipients. 
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1.2.1 Advantages of hydrophilic matrix system 
 
¾ Generally regarded as a safe excipient 
¾ Simple concept 
¾ Erodable – reducing ghost matrices 
¾ Easy to manufacture by 
 
 Direct compression 
 Wet granulation 
 Roller compaction 
 
¾ Possible to obtain different release 
 
1.2.2 Disadvantages 
 
¾ Need optimal rate controlling polymers 
¾ Scale of problems 
¾ Release of drug depends upon penetration of water and diffusion of drugs 
through hydrated matrix 
¾ If outer matrix layer erodes, complication in drug release profile takes place. 
 
These matrix tablets are resistant to dose dumping due to simple nature of 
formulation by hydrophilic colloid matrices are being robust they are unaffected by 
variation in ingredients. An important factor for modified release is the ability of 
hydrophilic polymers to readily hydrate and form a gel. 
 
            Hydroxy Propyl Methyl Cellulose (HPMC), which is commonly used in 
HPMS.  It is a mixed alkyl hydroxyl alkyl cellulose other containing methoxy & 
hydroxyl propyl groups.  The hydration rate of HPMC increases with increase in 
hydroxyl propyl content.  The solubility of HPMC is pH independent. It is non-ionic 
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and tolerant of most formulation variables and under very controlled conditions yield 
consistent properties of reproducible performance.  
 
Evidence suggests that the chemistry of HPMC encourages a strong tight gel 
formation compared to other . As a result, drug release rates have been sustained 
longer with HPMC than with equivalent levels of hydroxyl methylcellulose, ethyl 
cellulose (or) carboxyl methylcellulose. In addition, it was found that kinetics of 
initial hydration of cellulose ether is quite fast and relatively independent of 
substitution. Kinetics of gel growth is very similar for all substitution types of HPMC, 
observed apparent differences in swelling behavior are attributed to differential   
expansion of the glossy core7. 
 
Polymer chemistry plays a significant role since gel strength is controlled by 
polymer viscosity of concentration. Because HPMC is available in a wide range of 
molecular weights, effective control of gel viscosity is easily provided. It is the 
polymer most widely used in the formulation of solid, liquid semisolid and even 
controlled release dosage forms as gel forming agent. Water penetration, polymer 
swelling, drug dissolution and diffusion, matrix erosion from these dosage forms are 
controlled by the hydration of HPMC, which forms a gel barrier through which drug 
diffuses. 
 
1.2.3 Mechanism of drug release from hydrophilic matrix system8 
 
On exposure to aqueous fluid, hydrophilic matrices take up water, and 
polymer starts hydrating to form a gel layer. Drug release is controlled by diffusions 
barriers / or by surface erosion. An initial burst of soluble drug may occur due to 
surface leaching when a matrix containing a swellable glassy polymer comes in 
contact with an aqueous medium, there is an abrupt change from a glassy to a rubbery 
state which is associated with swelling process with time, water infiltrator deep into 
the case increasing the thickness by the gel layer. Concomitantly the outer layer 
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becomes fully hydrated and states dissolving or eroding. When water reaches the 
center of the system and the concentration of drug fells below the solubility value, the 
release rate of drug begins to reduce. At the same time, an increase in thickness of the 
barrier layer with time increases the diffusion path length, reducing the rate of drug 
release. Drug release kinetic associated with these gel – layer dynamic, range initially 
from Fickian to annomalous (Non – Fickian) and subsequently from quasi – Constant 
( near Zero order ) to constant.  
 
In general, two major factors control the drug release from swelling controlled 
matrix system. They  include 
 
 The rate of aqueous medium infiltration into the matrix, followed by a   
      Relaxation process (ie.,hydration,gelation,swelling). 
 The rate of matrix erosion. 
 
As a result of these simultaneous processes, two front are evident, a swelling 
front, where the polymer get hydrated, and an eroding front. The distance between 
these two fronts are called diffusion layer thickness. Diffusion layer thickness 
depends on the selective rate at which the swelling and eroding fronts move in 
relation to each other. If the polymer gets slowly, solvent can penetrate deep into the 
glassy matrix the dissolving the drug; there for gel layer thickness and it stability are 
council in controlling drug release.  
 
Swelling of HPMC matrix tablet was higher for higher a molecular weight. 
They attributed this to the large hydrodynamic volume occupied by higher molecular 
weight chain when hydrated. As the polymer chain becomes more hydrated and the 
gel becomes more dilute, the disentanglement concentration may be reached that is, 
the critical polymer concentration below which the polymer chain disentangle and 
detached from gelled matrix.  
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Fig – 1 
 
 Mechanism of Drug Release from Hydrophilic Matrix System 
 
The mechanism by which drug release controlled in matrix tablet is dependent 
on many variables, however the main principle is that the water soluble polymer 
present throughout the tablet hydrates on the outer tablet surface to form a gel lager. 
Throughout the life of the ingested tablet, the rate of drug release is deferment by 
diffusion (if soluble) through the gel and by the rate of tablet erosion (if insoluble). 
 
 
1.3BILAYER TABLET9,10:      
         
  A type of multilayered tablet in which instead of single tablet two layers were 
formulated by which two incompatible drugs can also be combined together in same 
formulation. 
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Fig – 2 
Bilayer Tabletting 
 
3.2Advantage11 
 
• A new platform technology for decreasing the chemical incompatibility.  
• Release of one drug as immediate and another drug as sustained.  
• Two layers are visible, so unbinded tablets can be easily detected.  
• Less coating material is required. 
 
3.3 Rationale for Development of Bilayer Tablet Technology: 
 
º Patient convenience 
º Patient Adherence. 
º Monotheraphy was prevented & Reduces pill burden  
º Combination of incompatabile drugs. 
º Ease of manufacture 
º Elegance to the product  
º Improved product stability. 
º Release of both the drugs starts immediately 
º Least probability of developing drug resistence used to treat different 
ailments at the same time in with one pill such as Hypertension, Heart 
disease, Hyperlipidemia, obesity & Diabetes. 
º Incompatability / stability issues can be resolved. 
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A new platform technology for decreasing the mechanical shear on double 
compressed products which can lead to decrease in unknown/process related 
impurities 
 
4.1Introduction of Gastric Retentive Drug  Delivery system12  
 
 Drug delivery systems are becoming increasingly sophisticated as 
pharmaceutical scientists acquire a better understanding of the physicochemical and 
biological parameters to their performance. Despite tremendous advancements in 
drug delivery, the oral route remains the preferred route for the administration of 
therapeutic agents because the low cost of therapy and ease of administration lead to 
high levels of patient compliance. 
 
Dosage forms that can be retained in the stomach are called gastro retentive  
drug delivery systems(GRDDS). The oral route is considered as the most promising 
route of drug delivery. Effective oral drug delivery may depend upon the factors such 
as gastric emptying process, gastrointestinal transit time of dosage form, drug release 
from the dosage form and site of absorption of drugs. Most of the oral dosage forms 
possess several physiological limitations such as variable gastrointestinal transit, 
because of variable gastric emptying leading to non-uniform absorption profiles, 
incomplete drug release and shorter residence time of the dosage form in the stomach. 
This leads to incomplete absorption of drugs having absorption window especially in 
the upper part of the small intestine, as once the drug passes down the absorption site, 
the remaining quantity goes unabsorbed12. The gastric emptying of dosage forms in 
humans is affected by several factors because of which wide inter- and intra-subject 
variations are observed. Since many drugs are well absorbed in the upper part of the 
gastrointestinal tract, such high variability may lead to non-uniform absorption and 
makes the bioavailability unpredictable. Hence a beneficial delivery system would be 
one which possesses the ability to control and prolong the gastric emptying time and 
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can deliver drugs in higher concentrations to the absorption site (i.e. upper part of the 
small intestine). All the above requirements can be met and effective delivery of the 
drugs to the absorption window, for local action and for the treatment of gastric 
disorders such as gastro-esophageal reflux, can be achieved by floating drug delivery 
systems (FDDS).  
 
NEED FOR GASTRIC RETENTIVE DRUG DELIVERY SYSTEMS: 
 
 To prolong the drug release and to reduce the variable gastric emptying 
process. After oral administration, such a DF would be retained in the stomach and 
release the drug there in a controlled and prolonged manner, So that the drug could be 
supplied continuously to its absorption sites in the upper gastro retentive dosage form 
can remain in the gastric region for several hours and hence significantly prolong the 
gastric residence time of drugs13. Prolonged gastric retention improves 
bioavailability, reduces drug waste, and improves solubility of drugs that are less 
soluble in a high pH environment. It is also suitable for local drug delivery to the 
stomach and proximal small intestines. Gastro retention helps to provide better 
availability of new products with suitable therapeutic activity and substantial benefits 
for patients. This mode of administration would best achieve the pharmacokinetic and 
pharmacodynamic advantages of CR-DFs of these drugs. 
 
 The need for gastro retentive dosage forms (GRDFs) has led to extensive 
efforts in both academia and industry towards the development of such delivery 
systems. These efforts resulted in GRDFs that were designed, in large part, based on 
the following approaches. 
 
(a) Low density form of the DF that causes buoyancy in gastric fluids. 
(b) High density DF that is retained in the bottom of the stomach. 
(c) Bioadhesion to stomach mucosa. 
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(d) Slowed motility of the gastrointestinal tract by concomitant administration of 
drugs or pharmaceutical excipients. 
(e) Expansion by swelling or unfolding to a large size which limits emptying of 
the DF through the pyloric sphincter. 
 
The current review deals with the gastro retentive approaches that has recently 
become leading methodologies in the field of controlled and site specific drug 
delivery system.    
 
Advantages of floating drug delivery system 
 
1. The HBS formulations are not restricted to medicaments, which are 
principally absorbed from the stomach. Since it has been found that these are 
equally efficacious with medicaments which are absorbed from the intestine 
e.g. Chlorpheniramine maleate. 
2. The HBS are advantageous for drugs absorbed through the stomach e.g. 
ferrous salts and for drugs meant for local action in the stomach and treatment 
of peptic ulcer disease14 e.g. antacids. 
3. The efficacy of the medicaments administered utilizing the sustained release 
principle of HBS has been found to be independent of the site of absorption of 
the particular medicaments. 
4. Administration of a prolonged release floating dosage form tablet or capsule 
will result in dissolution of the drug in gastric fluid. After emptying of the 
stomach contents, the dissolve drug available for absorption in the small 
intestine. It is therefore expected that a drug will be fully absorbed from the 
floating dosage form if it remains in solution form even at alkaline PH of the 
intestine. 
5. When there is vigorous intestinal movement and a short transit time as might 
occur in certain type of diarrhea, poor absorption is expected under such 
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circumstances it may be advantageous to keep the drug in floating condition in 
stomach to get a relatively better response. 
6. Gastric retention will provide advantages such as the delivery of drugs with 
narrow absorption windows in the small intestinal region. 
7. Many drugs categorized as once-a-day delivery have been demonstrated to 
have suboptimal absorption due to dependence on the transit time of the 
dosage form, making traditional extended release development challenging. 
Therefore, a system designed for longer gastric retention will extend the time 
within which drug absorption can occur in the small intestine 
8. Certain types of drugs can benefit from using gastro retentive devices. These 
include: 
 
¾ Drugs acting locally in the stomach; 
¾ Drugs those are primarily absorbed in the stomach; 
¾ Drugs those are poorly soluble at an alkaline pH; 
¾ Drugs with a narrow window of absorption; 
¾ Drugs absorbed rapidly from the GI tract; and 
¾ Drugs those degrade in the colon.                       
 
Disadvantages of floating drug delivery systems 
 
1) There are certain situations where gastric retention is not desirable. Aspirin 
and non-steroidal anti-inflammatory drugs are known to cause gastric lesions, 
and slow release of such drugs in the stomach is unwanted. 
2) Thus, drugs that may irritate the stomach lining or are unstable in its acidic 
environment should not be formulated in gastro retentive systems. 
3) Furthermore, other drugs, such as isosorbide dinitrate, that are absorbed 
equally well throughout the GI tract will not benefit from incorporation into a 
gastric retention system. 
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Factors affecting the floating drug delivery system 
 
• Nature of meal – feeding of indigestible polymers or fatty acid salts can 
change the motility pattern of the stomach to a fed state, thus decreasing 
the gastric emptying rate and prolonging drug release. 
• Caloric content – GRT can be increased by four to 10 hours with a meal 
that is high in proteins and fats. 
• Frequency of feed – the GRT can increase by over 400 minutes when 
successive meals are given compared with a single meal due to the low 
frequency of MMC15. 
• Gender – mean ambulatory GRT in males (3.4±0.6 hours) is less 
compared with their age and race matched female counterparts (4.6±1.2 
hours), regardless of the weight, height and body surface). 
• Age – elderly people, especially those over 70, have a significantly longer 
GRT. 
• Posture – GRT can vary between supine and upright ambulatory states of 
the patient. 
• Concomitant drug administration – anticholinergics like atropine and 
propantheline, opiates like codeine and prokinetic agents like 
metoclopramide and cisapride; can affect floating time. 
• Biological factors – diabetes and Crohn’s disease, etc. 
 
Biological aspects of GRDFS: 
 
Role of GI tract: Stomach 
 
The stomach is J-shaped organ located in the upper left hand portion of the 
abdomen, just below the diaphragm. It occupies a portion of the epigastric and left 
hydrochondriac region. The main function of the stomach is to store the food 
temporarily, grind it and then release it slowly into the duodenum. Due to its small 
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surface area very little absorption takes place from the stomach. It provides barrier to 
the delivery of drugs to small intestine. 
 
 
Fig.3  
Anatomy of Stomach 
 
The stomach is divided into three anatomical regions. I)Fundus  ii) Body and 
iii) Pylorus (or antrum). The proximal stomach consisted of Fundus and body, which 
serves as a reservoir for ingested materials, whereas the distal region (pylorus) is the 
major site of mixing motions, acting as a pump to propel gastric contents for gastric 
emptying. Gastric emptying occurs both in fasting as well as fed states16. 
 
The GI tract is always in a state of continuous motility. There are two modes 
of motility pattern. The digestive mode and interdigestive mode. In case of fasted 
state an interdigestive series of electrical events occurs in cyclic manner both through 
stomach and small intestine every 2-3 hr. This electrical activity is termed as 
 
 
 
 
INTRODUCTION  
 
15 
 
interdigestive myoelectric cycle or migrating myoelectric complex (MMC), which is 
further divided into four phases.18,19 
 
Phase I   :  Period of no contraction. 
Phase II   :  Period of intermittent contraction. 
Phase III   :  Period of regular contractions at the maximal frequency  
that migrate distally. 
Phase IV   :  Period of transition between phase III and phase I. 
 
Phase III has a housekeeping role and serves to clear all indigestible materials 
from the stomach and small intestine. Consequently, a controlled-release 
gastrointestinal drug delivery system must be capable of resisting the house keeping 
action of phase III. Studies revealed that in the fed state, the gastric emptying rate is 
slowed since the onset of MMC is delayed. It can be concluded that feeding results in 
a lag time before onset of gastric emptying cycle. 
 
Approaches to gastric retention17 
 
A number of approaches have been used to increase the GRT of a dosage form in 
stomach by employing a variety of concepts. These include – 
 
a) Floating Systems 
b) Bio/Muco-adhesive Systems 
c) Swelling and Expanding Systems 
d) High Density Systems 
e) Incorporation of Passage Delaying Food Agents 
f) Ion Exchange Resins 
g) Osmotic Regulated Systems  
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Floating Systems: 
 
 Floating Drug Delivery Systems (FDDS) have a bulk density lower than 
gastric fluids and thus remain buoyant in the stomach for a prolonged period of time, 
without affecting the gastric emptying rate. While the system is floating on the gastric 
contents, the drug is released slowly at a desired rate from the system. After the 
release of the drug, the residual system is emptied from the stomach. This results in 
an increase in the GRT and a better control of fluctuations in the plasma drug 
concentrations. Floating systems can be classified into two distinct categories, 
noneffervescent and effervescent systems. 
 
Effervescent system:  
 
  These are matrix types of systems prepared with the help of  swell able 
polymers such as methyl cellulose and chitosan and various effervescent 
compounds.eg,sodium bicarbonate ,citric acid and tartaric acid.  
 
      They are formulated in such a way that when in contact with the acidic gastric 
contents,co2 is liberate and gas entrapped in swollen hydrocolloids which provides 
buoyancy to the dosage forms. 
 
Non-effervescent system 
 
 These system use a gel forming or swell able cellulose type hydrocolloids and 
matrix-forming polymers like polyacrylate, polycarbonate, etc. 
 The formulation method of this system is thoroughly mixing the drug and the 
gel forming hydrocolloid. After oral administration this dosage form swells in 
contact with gastric fluids and attains the bulk density of < 1. 
 The air entrapped within the swollen matrix imparts buoyancy to the dosage 
forms.  
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FLOATING BILAYER TABLET 
 
These are also compressed tablet as shown in Fig 3 and containing two layer i.e., 
i. Immediate release layer and 
ii. Sustained release layer. 
 
 
 
Fig 4 
Floating Bilayer Tablet 
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1.5 DIABETES MELLITUS18,19 
  
 Diabetes mellitus is a metabolic disorder characterized by high blood sugar 
(glucose) level or hyperglycemia, glycosuria, hyperlipemia, negative nitrogen balance 
sometimes ketonemia. The above symptoms results in defect of insulin secretion or 
action or both. A wide spread pathological change is thickening of capillary basement 
membrane, increase in vessel wall matrix and cellular proliferation resulting in 
vascular complications like lumen narrowing, early atherosclerosis, sclerosis of 
glomerullar capillaries, retinopathy, neuropathy and  peripheral vascular 
insufficiency. Diabetes mellitus consists of group of disorders involving distinct 
pathogenic mechanism with hyperglycemia as the common effect. Regardless of the 
cause, the disease is associated with insulin deficiency, which may be total or partial 
or relative when viewed in respect of co-existing insulin resistance. Diabetes is a 
major medical and economical problem. Hence, in order to treat this highly prevalent 
condition, many pharmaceutical preparations have emerged in the recent past which 
are termed as Antidiabetic agents. 
  
 Diabetes mellitus is the commonest endocrine disorder also now recognized 
serious global health problem. It affect more than 100 million of the people 
worldwide. 
 
The INTERNATIONAL DIABETES FEDERATION (IDF) estimates the 
total number of people in India with diabetes to be around 50.8 million in 2010, rising 
to 87.0 million by 2030. In more developed societies, the prevalence of  Diabetes 
mellitus has reached about 6%  and even more alarmingly, among obese white 
adolescents 4% had diabetes and 25% had abnormal glucose tolerance. Some 90% of 
diabetic individuals have Type 2 diabetes mellitus when compared to Type 1 diabetes 
mellitus20.  Diabetes is a chronic illness that requires continuing medical care and 
patient self-management education to prevent acute complications and to reduce the 
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risk of long-term complications.The lifestyle modification, diet and exercise of 
moderate intensity are used to improve insulin sensitivity and are recommended as an 
integral part of treatment of Type 2 diabetes21. When the lifestyle modification, diet 
and exercise fails to maintain the adequate glyceamic control, oral hypoglycemic 
agents are introduced as a treatment approach. 
 
Diabetes Mellitus can be categorized into several types but the two major types are  
 
Ö Type 1 Diabetes Mellitus 
 Also known as Insulin dependent diabetes mellitus (IDDM) or 
juvenile-onset diabetes.  
 
Ö Type 2 Diabetes Mellitus 
 Non-insulin dependent diabetes mellitus (NIDDM) or maturity- onset 
diabetes.  
 
Type 2 Diabetes would affect about 98% persons above 45 years of age. 
Type 2 diabetes is caused by two primary metabolic defects: 
 
  Progressive pancreatic β-cell dysfunction and insulin resistance. β-Cell 
dysfunction superimposed on insulin resistance leads to hyperglycemia and 
subsequently to type 2 diabetes. Typically, at the time of diabetes diagnosis, nearly 
50% of β-cell function has been lost and less than 60% of normal insulin sensitivity is 
present. 
  
 Oral Hypoglycemic Agents (OHAs) can be used either alone or in 
combination with other OHAs or insulin. The Canadian Diabetes Association 2003 
Clinical Practice Guidelines for the Prevention and Management of Diabetes 
recommends a target hemoglobin A1C concentration of 7.0% or less for all patients 
with diabetes. Currently, there are five major classes.  
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Oral Anti Diabetic agents22: 
Sulphonylureas 
  – insulin secretagogues that target β –cell dysfunction. 
 
 Metformin 
  – a biguanide that reduces hepatic glucose production and improves insulin 
sensitivity. 
 
Thiazolidinediones 
  – insulin sensitizers that lower peripheral insulin resistance 
 
 β-glucosidase inhibitors 
  – intestinal enzyme inhibitors that slow carbohydrate absorption; and  
 
Meglitinides  
  – rapid but short-acting, 
 
The goal levels of diabetes related parameters during treatment is given in Table No. 
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    Table no: 1 
  Blood-glucose targets for people with Diabetes 
 
Parameter Normal Goal Action suggested if 
Pre-prandial Fasting 
Glucose 
<110 mg/dl 80-120 mg/dl <80 or >140 mg/dl 
postprandial Glucose <140 mg/dl <140 mg/dl >180 mg/dl 
Bedtime <120 mg/dl 100-140 mg/dl <100 or >160 mg/dl 
HbA1c ≤ 6% < 6.5 % >8 % 
 
 Insulin is also important in type 2 DM when blood glucose levels cannot be 
controlled by diet, weight loss, exercise and oral medications.  
 
Insulin is indicated in the following situations: 
 
1) When diet and oral hypoglycemic drugs fail to control hyperglycemia and 
achieve therapy targets 
2) Diabetes during pregnancy when diet alone is inadequate 
3) When oral hypoglycemic drugs are contraindicated 
4) During stressful conditions such as infection and surgery. 
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Combination therapy: 
 
  It was always beneficial to switch over the patients on combination therapy, 
when there is high secondary failure associated with monotherapy and devastating 
long term consequence of poor glycemic control. Areasonable goal of treatment is to 
maintain good glycemic control through combination therapy so as to keep HbA1c 
value below 7% for a particular patient. Initiation of combination drug therapy at low 
dosages can minimize the side effects associated with high dose therapy of either 
agent, yield additive clinical benefits, and possibly curtail cost of treatment. For many 
drugs, 50% of the dosage needed to achieve the maximal therapeutic effect will 
produce well over 50% of that effect. 
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Table no: 2 
Comparison of Type 1 & type 2 DM23 
 
Parameters Type 1 Type 2 
Age of onset <40 years >50 years 
Classical symptoms Usually present Few or none 
Duration of symptoms weeks Months/years 
Body weight Normal/low Obese usually 
History of weight loss yes No 
Prone to ketoacidosis yes No 
Insulin levels Very low Low/Normal/High 
Insulin resistance Absent Present 
Rapid death without 
insulin 
yes No 
Presence of 
autoantibodies 
yes No 
Diabetic complications at 
diagnosis 
No 10-20% 
Family history of diabetes No Yes 
Presence of other auto 
immune disease 
Yes No 
Complications Microvascular, 
Macrovascular 
Microvascular, 
Macrovascular 
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24Biswajit Biswal et al., (2011) were studied on designing floating Bilayer tablet 
of Trimetazidine Dihydrochloride by dry granulation method. The formulated 
tablets were evaluated for weight variation, hardness, friability, drug content, 
floating lag time, total buoyancy time and in vitro release studies. He reported that 
the combination of low viscosity polymer and high viscosity polymer would 
increase the release rate. 
25Rubina Reichal et al., (2011) were developed the floating tablet of Glimepiride 
by direct compression technique by using various viscosity grades of HPMC k4M, 
HPMC K100 and Carbopol 934P to prolong the gastric residence time and to 
increase the drug bioavailability.  
26Gaur et al., (2011) were designed the floating tablet of Metformin HCl by 
optimizing gas generating agent to improve the buoyancy time. He found that 
increasing concentration of sodium bicarbonate results in bursting effect. 
27Padmavathy et al., (2011) were studied on formulating floating tablet of 
Oflaxacin using HPMC by wet granulation technique. She reported that the drug 
release rate decreased as the concentration of high viscosity polymer increased. 
28Pramod patil et al., (2011) were fabricated floating tablet of Oflaxacin by wet 
granulation method. He concluded that HPMC K100 shows decrease in floating 
lag time & increase the duration of floating time. This is due to high viscosity 
polymer HPMC K100 maintains the integrity of the tablet for longer duration. 
29Sivabalan et al., (2011) were designed floating Glipizide tablet by direct 
compression technique. He found that by combining the polymer like   HPMC, 
EC (ethyl cellulose) and MCC (microcrystalline celluose) shows better in vitro 
release than polymers alone. 
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30Garg shiv kumar et al., (2011) were studied on Gastroretentive floating tablet 
of Aceclofenac by using HPMC K4M, HPMC K15M by direct compression 
method. He found that drug release rate decreased in order of HPMC K grade < 
HPMC E grade with increasing macromolecular weight, the degree of 
entanglement of the polymer chain increase. So, the mobility of the 
macromolecules in the fully swollen system decreased this leads to decreased drug 
diffusion and decreased drug release with increase in molecular weight. 
31Madhu soodan Sharma et al., (2011) designed the floating tablet of 
Cefpodoxime proxetil by employing different viscosity grades of HPMC 
K4M,K15M,K100M at different drug to polymer ratio. He reported that the 
different viscosity grades in different ratio would effect the drug release. 
32Laxmi goswami,et al., (2011) fabricated Bilayer Floating Tablet of Metformin 
HCl and Pioglitazone was done by direct compression using polymers like 
hydroxyl propyl methyl cellulose(HPMC),Carbopol, Polyvinylpyrrolidone to 
facilitate immediate release of pioglitazone and sustained release of Metformin 
HCL. The formulated tablets remain buoyant over a period of 12-20 hrs and 
released  more than 80% of drug in study period. 
33Dinesh kumar et al., (2010) formulated the Bilayer tablet of Raniditine by 
direct compression method. HPMC K100, HPMC K4M, HPMC E-15 were used 
as gel forming agents and sodium bicarbonate are used as gas generating agent. 
The formulated tablets were evaluated for weight variation, drug content, floating 
lag time and duration of floating. The results shows that good floating property 
and sustained release character. 
34Ajay Bagherwal et al., (2010) studied on formulating Ciprofloxacin HCl 
floating tablet by dry granulation method. The formulated tablets were 
characterized for weight variation, hardness, friability, drug content, floating lag 
time, total buoyancy time and in vitro dissolution study. From the release studies 
it was concluded that increase in polymer concentration decreases the release rate. 
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35Borkar et al., (2010) studied the effects on viscosity of polymer in formulating 
Bilayer gastroretentive floating drug delivery system of Cefpodoxime proxime. 
From the study it was concluded that the drug release decrease with increase in 
concentration of polymer. To overcome an initial burst effect, the high viscosity 
HPMC polymer used. High viscosity polymer give prolonged floating and drug 
release when compared to low viscosity polymer. 
36Mohammed asif et al., (2010) fabricated on gastroretentive dosage form of 
Fluvastatin sodium. He concluded that viscosity was the major effect affecting the 
release and floating property. On increasing the concentration of hydrogel 
polymer it decreases the release rate.        
37Rajashree masareddy et al., (2010) were designed floating matrix tablet of 
Riboflavin by direct compression method using HPMC K4M and Carbopol 971P 
mixture. The studies revealed that combination of low viscosity and high viscosity 
polymer the was found to better for formulating sustained release. 
38Margret chandira et al., (2010) were formulated gastroretentive drug delivery 
system of gastro prokinetic drug Itopride HCl employing polymers like HPMC 
K100M, HPMC K15 & Carbopol934P. she proved that drug release rate was 
decreased as the viscosity of the polymer increased. 
39Barhate et al., (2010) were optimized floating Bilayer tablet of Famotidine by 
wet granulation technique. He concluded that drug release rate deponds on the 
combination of low viscosity and high viscosity. 
40Anilkumar shinde et al., (2010) were studied on formulating floating tablet of 
Cephalexin using HPMC as rate retarding agent, sodium bicarbonate as gas 
generating agent. The studies revealed that increase in concentration of polymer 
the release rate was decreased. 
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41Dalavi et al., (2009) fabricated on Gastroretentive drug delivery system of an 
antiretroviral agent Zidoviduine and evaluated on statistical analysis. His studies 
confirmed that the formulation which contains high polymer concentration, were 
able to keep their integrity and show better control on in vitro release studies, with 
a desired slower release rate for a prolonged period of time.      
42Selimreza et al., (2009) designed in formulating theophylline loaded 
gastroretentive floating tablet by employing HPMC K4M & HPMC K15 and gas 
generating agent. He reported that increase in amount of floating agent cause the 
decrease in floating time and high amount of hydrophilic polymers would 
favoured for formulating Sustained release. 
43Swati jagdale et al., (2009) were studied on formulating the gastroretentive 
drug delivery system of propranolol HCl various polymers like HPMC KM, 
HPMC E-15, HPC in various proportions. He found that low viscosity polymers 
increase the floating lag time but decrease the release rate. The high viscosity 
polymer HPMC K4M gave good release rate when compared to HPMC E-15. 
44Ravikumar et al., (2009) studied on designing effervescent floating tablet of 
Famotidine by direct compression technique. His studies confirms that the 
formulation in combination of different viscosity grades of HPMC polymer shows 
better release and it is suitable for formulating SR formulations. 
45Kshirsagar et al., (2009) were studied on effect of different viscosity grade 
HPMC polymers on gasteoretentive drug delivery of Metformin HCl. He reported 
that viscosity of polymer increases in the formulation the release decreases, which 
may be due to increased strength of the gel matrix of the HPMC. 
46Shailesh et al., (2008) studied on designing gastric floating matrix tablet by 
using combination of polymers. He found that HPMC was a suitable polymer for 
developing floating tablet. 
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47Patil et al., (2008) designing floating tablet of Amlodipine besylate by 
incorporating different grades of polymers. His study reveals that by combining 
HPMC K100M & HPMCK15M the release rate was prolonged. 
48Tanwar et al., (2007) formulated famotidine floating tablet by using two 
different grades of Methocel K100 and Methocel K15M. He found that Methocel 
K100 were found it is suitable for floating technique due to its prolonged action.     
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3.1 DRUG PROFILE  
3.1.1 Metformin hydrochloride 49,50,51 
Chemical Structure 
 
Category 
 Antidiabetic (Biguanides) 
Chemical name 
1,1-Dimethylbiguanide hydrochloride 
 Empirical formula 
 C4H11N5, HCL 
Molecular Weight 
 165.63 g/mol 
Description 
Nature 
 White to off white crystalline powder; hygroscopic. 
Solubility 
 Freely soluble in water 300mg/ml at 2°C. 
 Practically insoluble in acetone, ether & chloroform. 
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pKa 
 The pKa of Metformin is 12.4 
pH 
 The pH of a 1% aqueous solution of Metformin Hydrochloride is 6.68 
Storage  
 Protected from light and moisture 
Pharmacokinetic data 
Bioavailability 
 50-60% 
Metabolism 
 None 
Half life 
 Plasma half life: 1.5-3 hours 
 Elimination half life: 6.2 hours 
Distribution  
 654-358 L 
Excretion 
 Active renal tubular secretion. 
Pharmacological action 
 Metformin decreases blood glucose levels by decreasing hepatic glucose 
production, decreasing intestinal absorption of glucose, and improving insulin 
sensitivity by increasing peripheral glucose uptake and utilization. These effects 
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are mediated by the initial activation by Metformin of AMP-activated protein 
kinase (AMPK), a liver enzyme that plays an important role in insulin signaling, 
and the metabolism of glucose and fats. Activation of AMPK is required for 
Metformin  inhibitory effect on the production of glucose by liver cells. 
Clinical benefits of Metformin hydrochloride 
 Metformin hydrochloride is effective in the treatment of polycystic ovary 
disease. Its ability to lower insulin resistance in these women can result in 
ovulation and possibility for pregnancy.   
Dose  
 250-1000 mg 
Table  No - 3 
Marketly available drug of Metformin hydrochloride 
Brand name Dose Company name 
Atformin 500mg Active HL 
Bigesens 500mg Zydus carila 
G-red SR tab 250mg Orchid 
Formin 500mg Alkem 
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3.1.2 Glimepiride 7,50,51 
Chemical Structure 
 
Category 
 Antidiabetic (Sulfonylurea) 
Chemical name 
 1-[[4-[2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)-
ethyl]phenyl]sulphonyl]-3-trans-(4-methylcyclohexyl)urea 
Empirical formula 
 C24H34N4O5S 
 
Molecular Weight 
 460.62  
Description 
Nature 
 White crystalline powder  
Solubility 
 Freely soluble in dimethyl foramide, Acetonitrile. Slightly soluble in weak 
acid and base.  
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Storage  
 Store in a well closed containers, at a temperature not exceeding 25°C  
Pharmacokinetic data 
Bioavailability 
 Completely (100%) absorbed following oral administration. 
 
Metabolism 
 Hepatic metabolism. glimepiride is completely metabolized by oxidative 
biotransformation  
Half life 
 5-7 hours  
Distribution  
19.8 ± 12.7 L [Single Dose] 
37.1 ± 18.2 L [Multiple Dose] 
Excretion 
 Hepatic (biliary excretion) 
Pharmacological action 
 The pharmacological of action of Glimepiride in lowering blood glucose 
appears to be dependent on stimulating the release of insulin from functioning 
pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. 
Glimepiride likely binds to ATP-sensitive potassium channel receptors on the 
pancreatic cell surface, reducing potassium conductance and causing 
depolarization of the membrane. Membrane depolarization stimulates calcium ion 
influx through voltage-sensitive calcium channels. This increase in intracellular 
calcium ion concentration induces the secretion of insulin. 
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Clinical benefits of Glimepiride 
 Best achieving the hypoglycemic effect. 
Dose  
 1-2 mg/day 
Table No : 4 
Marketed  available Glimepiride 
  
Brand name Dose Company name 
Amaryl-fc tab 1mg Sanofi Aventis 
Azulix 1mg Torrent 
Chempride 1mg chemch 
Glimtide 1mg Orchid 
Glimpid 1mg Ranbaxy 
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3.2 Execipients profile52 
3.2.1 Hydroxy Propyl Methyl Cellulose (HPMC) 
Chemical structure   
 
  
    
 
  
 
 
 
Molecular Formula 
 
[C6H7O2(OH)3-(OCH3)-(OCH3CH(OH)-CH3)]n 
 
Synonym 
 
Methyl hydroxyl propyl cellulose, Methyl cellulose, Propylene glycol 
ether. 
 
Chemical name 
Cellulose 2-hydroxy propyl methyl ether. 
 
Non Proprietary Name 
 
BP   :  Hypermellose 
USP :  Hydroxy Propyl Methyl Cellulose. 
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Molecular Weight 
Approximately 86,000. 
 
Category 
Tablet binder, film former, coating agent, suspending agent, stability 
agent. 
 
Description 
White (or) Yellowish white fibrous (or) granular powder, almost odorless, 
hygroscopic after drying. 
Solubility 
Soluble in mixtures of ethanol & methylene chloride, practically insoluble 
in hot water, acetone, ethanol, toluene & ether. It swells in cold water forming an 
opalescent viscous colloidal solution.  
 
Properties 
 
¾ Resistance to salting out: HPMC is nonionic cellulose ether and it is not a 
polyelectrolyte. The aqueous solution of HPMC is comparatively stable                        
even in the presence of metal salts or organic electrolytes. However, when 
the concentration of electrolytes exceeds a certain limit, gelation and 
precipitation may result. 
¾ Surface activity: An aqueous solution of HPMC has a high surface 
activity and functions as a protective colloid agent, emulsion stabilizer and 
dispersant. 
¾ Thermal gelation: An aqueous solution of HPMC will gel or precipitate 
when heated to a certain temperature, but it reverts to the original solution  
state on Subsequent cooling. The temperature at which gelation or 
precipitation occur depends on the type of HPMC, its concentration and 
the rate of heating. 
¾ pH stability: The viscosity of an aqueous solution of HPMC is hardly 
affected by acid or alkali, and the product can develop an original viscosity 
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in the range of3.0~11.0. Therefore, the solution viscosity tends to keep 
stable during prolonged storage. 
¾ Water retention: HPMC is a high effective water retention agent. Its                     
      pharmaceutical grade product can be widely used in food, cosmetics and   
     many other fields. 
¾ Film forming: HPMC provides a strong, flexible and transparent film 
having a good barrier property against oil and grease. In food application, 
this property is often utilized for water retention and oil adsorption. 
¾ Cohesiveness (Binding property): HPMC, as a high performance binder, 
can also be used for molding food and medicine. 
 
Specific Properties 
Melting point 
190-200° 
Acidity/Alkalinity 
5.5-8.0 for 1% w/w aqueous solution                                             
Specific Gravity 
1.26 
Density 
0.25-0.71 g/cm3. 
Viscosity grades 
Commercially available viscosity grades are distinguished by a number 
indicative of apparent  viscosity in millipascal seconds in 2% w/v solution at 20°.  
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                  Grades   Viscosity (cps) 
 HPMC K4M                 4000 
 HPMC E-5         5 
HPMC E-15         15 
Application 
                          Uses                                                     Concentration (%) 
    Extended release Matrix formulation   15-35 
                  Tablet Binder                                                      2-6 
               Tablet film coating                                             2-20      
 
• HPMC was used in the treatment of tear deficiency.  
• It was a versatile and non-creative granulating agent. 
• It swells in water & in virtually in all GIT fluids and it may expect to 
retard disintegration & dissolution time of drugs in the resulting tablets 
when wet granulation is employed. 
 
Stability & Storage 
 
Bulk material is stored in an air tight container and in cold & dry place. 
Increase in temperature decrease the viscosity of the solution. 
 
Safety 
 HPMC was regarded as non-toxic & non-irritant, although excessive 
consumption causes laxative effect. 
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3.2.2 Sodium Bicarbonate 
Chemical structure  
 NaHCO3  
Synonym  
 Sodium Hydrogen Carbonate, Monosodium carbonate, Sodium Acid 
Carbonate. 
Chemical Name 
 Carbonic acid monosodium salt 
Non-Proprietary Name 
BP :  Sodium Bicarbonate 
 USP :  Sodium Bicarbonate 
Molecular Weight 
 84.01 
Category  
 Alkalizing agent, Therapeutic agent. 
Description  
 Odorless, white, Crystalline powder with a saline, slightly alkaline taste. 
Solubility  
 Practically insoluble in ethanol and ether 
 Soluble in water. 
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Typical properties 
Acidity/ Alkalinity  
 pH=8.3 for a freshly prepared 0.1M aqueous solution at 25°C, alkalinity 
increases on standing, agitation or heating. 
Density  
 0.869-2.173 g/cm3 
Freezing point depression  
 0.381°C 
Melting point 
 270°C 
Moisture content 
 Below 80% relative humidity, the moisture content is less than 1%w/w. 
Above 85% relative humidity, sodium bicarbonate rapidly absorbs excessive 
amounts of water and may start to decompose with loss of carbon dioxide. 
Osmolarity: 
 1.39%w/v aqueous solution is isotonic with serum. 
Refractive index 
 1.3344 
Applications  
 Generally used as a source of carbon dioxide in effervescent tablet and 
granules. It is also widely used to produce or maintain an alkaline pH in a 
preparation. Therapeutically, sodium bicarbonate may be used as an antacid and 
as a source of the bicarbonate anion in the treatment of metabolic acidosis. It is 
also used as a component of oral rehydration salts.  
  
 
 
DRUG AND EXCIPIENTS PROFILE   
 
41 
 
Table No : 5 
Pharmaceutical application of Sodium Bicarbonate  
 
Uses Concentration (%) 
Buffer in tablets 10-40 
Effervescent tablet 25-50 
Isotonic injection/infusion 1.39 
  
3.2.3 Citric acid 
 Chemical structure 
 
Synonym  
 2-hydroxypropane-1,2,3-tricarboxylic acid monohydrate. 
Chemical Name 
 2-Hydroxy-1,2,3-propanetricarboxylic acid monohydrate 
Nonproprietary Names 
BP :  Citric acid monohydrate 
 USP : Citric acid 
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Molecular Weight 
 210.14 
Category 
 Acidifying agent; antioxidant; buffering agent; chelating agent; flavor 
enhancer. 
Description 
  It is colorless or translucent crystals or as a white crystalline, efflorescent 
powder. It is odorless and has a strong acidic taste. The crystal structure is 
Orthorhombic. 
 
Solubility: 
 Soluble 1 in 1.5 parts of ethanol (95%) and 1 in less than 1 part of water; 
sparingly soluble in ether. 
 
Typical Properties 
Acidity/alkalinity: 
 
 pH = 2.2 (1% w/v aqueous solution) 
 
Dissociation constant: 
 
 pKa1  :  3.128 at 25°C; 
 pKa2  :  4.761 at 25°C; 
 pKa3  :  6.396 at 25°C. 
 
Density: 
 1.542 g/cm3 
 
Heat of combustion: 
 -×1972 kJ/mol (-×471.4 kcal/mol) 
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Heat of solution: 
 -¼16.3 kJ/mol (-¼3.9 kcal/mol) at 25°C 
 
Hygroscopicity: 
 
 At relative humidities between about 65% and 75%, citric acid absorbs 
insignificant amounts of moisture, but under more humid conditions substantial 
amounts of water are absorbed. 
 
Melting point: 
 
 100°C (softens at 75°C) 
 
Viscosity (dynamic): 
 
6.5 mPa s (6.5 cP) for a 50% w/v aqueous solution at 25°C. 
 
Stability and Storage Conditions 
 
Citric acid loses water of crystallization in dry air or when heated to about 
40°C. It is slightly deliquescent in moist air. Dilute aqueous solutions of citric acid 
may ferment on standing. 
 
The bulk monohydrate or anhydrous material should be stored in airtight 
containers in a cool, dry place. 
 
Safety  
 
Orally ingested citric acid is absorbed and is generally regarded as a 
nontoxic material when used as an excipient. However, excessive or frequent 
consumption of citric acid has been associated with erosion of the teeth. 
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3.2.4 Povidone 
Chemical structure 
 
 
Molecular Formula 
C6H9NO  
 
Synonyms 
 Kollidon; plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; polyvidone; 
polyvinylpyrrolidone;pvp; 1-vinyl-2- pyrrolidinone polymer 
 
Chemical name 
 1-ethenyl-2-pyrrolidinone homopolymer 
 
Non proprietary name 
 Bp  :  povidone 
Usp  :  povidone 
 
Molecular weight 
 2500-3000000 
 
Category 
 Disintegrant; dissolution aid; suspending agent; tablet binder. 
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Description 
Povidone occurs as a fine, white to creamy-white coloured, odourless or 
almost odourless ,hygroscopic powder. Povidones with k- values equal to or lower 
than 30 are manufactured by spray- drying and occur as spheres.  
 
Solubility 
Freely soluble in acids, chloroform, ethanol, ketones, methanol, and water; 
practically insoluble in ether, hydrocarbons, and mineral oil. In water, the 
concentration of a solution is limited only by the viscosity of the resulting 
solution, which is a function of the k-value. 
 
Typical Properties 
 
Density (bulk)  :  0.29-0.39g/cm3 
Density (tapped) :  0.39-0.54g/cm3 
Density (true)  :  1.180g/cm3 
 
Melting point:  
 
  Softness at 1500c 
 
Moisture content:  
 
               Povidone is very hygroscopic, significant amounts of moisture being 
absorbed at low relative humidities. 
 
Stability &storage 
 Povidone may be stored under ordinary conditions without under going 
decomposition or degration. However, since the powder is hygroscopic, it should 
be stored in an airtight container in a cool, dry place. 
 
Safety 
              Povidone may be regarded as essentially nontoxic. Povidone additionally 
has no irritant effect on the skin and causes no sensitization. 
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3.2.5 Magnesium Stearate 
Chemical Structure  
 
Synonym 
 Stearic acid Magnesium salt, Magnesium Octadecanoate metallic stearate. 
Chemical Name 
 Octadecanoic acid Magnesium salt. 
Non-Proprietary Name 
BP/ USPNF  :  Magnesium stearate 
Molecular formula  
 C36H10MgO4 
Molecular Weight 
 591.27. 
Category 
 Tablet & Capsule Ant adhesive, Lubricant & Glidant. 
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Description 
 Fine, White precipitated, milled, impalable powder of low bulk density 
having a faint characteristic odor and taste, poorly flowing cohesive powder, 
greasy to touch and adheres to skin. 
Solubility 
 Insoluble in ethanol (95%) & water. Soluble slightly in warm benzene & 
hot alcohol. 
Properties 
Density 
 1.03-1.08 g/cm3. 
Melting point 
361 K / 88°C 
Storage & Stability 
Magnesium Stearate is non-toxic following oral administration while 
inhalation is harmful. 
Applications  
 
 Magnesium Stearate is primarily used as lubricant in tablet & capsule 
manufacturing at 0.25-5% concentration. 
 Used in cosmetics to prepare barrier creams.  
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3.2.6 Talc 
Chemical Structure  
                               
Synonym 
 Hydrous magnesium calcium silicate; hydrous magnesium silicate 
Chemical Name 
 Talc  
Non-Proprietary Name 
      BP  :  purified talc  
     USP :  talc  
Molecular formula  
 Mg6 (Si2O5)4(OH)4. 
 
Molecular Weight 
 379.27 gm 
Category 
 Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule 
lubricant. 
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Description 
 Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free 
from grittiness. 
Solubility 
 Practically insoluble in dilute acids and alkalis, organic solvents, and 
water. 
Properties 
Acidity/alkalinity 
pH = 7–10 for a 20% w/v aqueous dispersion. 
 
Hardness (Mohs) 
1.0–1.5 
 
Moisture content 
 Talc absorbs insignificant amounts of water at 25°C and relative 
humidities up to about 90%. 
Specific gravity 
2.7–2.8 
Storage & Stability 
Talc is a stable material and may be sterilized by heating at 160°C for not 
less than 1 hour. 
 Talc should be stored in a well-closed container in a cool, dry place. 
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Applications 
 It is widely used in solid dosage forms as a Glidant and Lubricant. 
  
Table No : 6 
Application of Talc 
  
                        Uses  Concentration 
               Dusting powder  90.0–99.0 
Glidant and tablet lubricant  1.0–10.0 
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4.1 AIM AND OBJECTIVE 
  The aim of the present work is to formulate and evaluate Bilayer Floating     
 tablets of Metformin HCl and Glimepiride for the treatment of Type 2    
 Diabetes Mellitus. 
 To formulate Metformin HCl as sustained release layer and Glimepiride as  
 immediate release layer.  
 To formulate and evaluate sustained release layer by using Hydrophilic          
 polymers like HPMC K4M, HPMC E-5 and HPMC E-15. 
 To formulate and evaluate sustained release layer by using combined 
 Hydrophilic polymers like HPMC K4M+HPMC E-5, HPMC E-5+HPMC 
 E-15, HPMC K4M+HPMC E-15. 
 Individual tablet were formulated and optimized separately by in vitro 
studies.  
 To study the effect produced by employing various viscosity grades of 
Hydrophilic polymer    
 Reduce dose frequency. 
 Economically cheaper. 
 Reduce pill burden. 
 Providing easy medication. 
 Improve patient compliance. 
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Need for present study 
 In Type2 Diabetes Mellitus patient Sulphonylureas and the Biguanide are 
the two most commonly used prescribed drugs for oral treatment. 
 In Sulphonylureas, Glimepiride were mostly prescribed drug because due 
to its low dosage (1-2mg) and its potent activity on glycemic control. In 
Biguanide, Metformin HCl are mostly prescribed drug, since it is an older and 
effective drug for maintaining blood glucose level. 
 Combination of Metformin HCl and Glimepiride were found to be very 
useful in Type 2 Diabetes Mellitus when compared with treatment of Metformin 
HCl and Glimepiride alone. In combination drug therapy, the blood glucose level 
is maintained  in a very good manner. 
 The floating technique was employed to improve their absorption by 
increasing their gastric residence time and to reduce the unabsorbed drug (wastage 
of drug). Metformin HCl and Glimepiride is the drug, which does not cause any 
irritation on Gastric intestinal tract (GIT), and its absorption takes place in the 
upper part of the intestine. 
 From the above consideration the Metformin HCl and Glimepiride are 
suitable drugs for combination  treatment of type 2 diabetes mellitus and to  
formulate as floating bilayer tablets.  
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5. PLAN OF WORK: 
1. Preformulation studies: 
¾ Active pharmaceutical ingredient characterization such as description,     
     etc, 
¾ Identification of absorption maxima of the drug by UV. 
¾ Assessment of compatibility among formulation excipient by FT-IR 
analysis. 
 
2. Formulation development 
Development of sustained release layer tablets: 
¾ Sustained release layer by using synthetic Hydrophilic polymer of 
different viscosity  grade of same polymer. 
i.e.,Metformin hydrochloride +HPMC K4M 
Metformin hydrochloride +HPMC E-5 
Metformin hydrochloride +HPMC E-15 
 
¾ Sustained release by using combined hydrophilic polymer of different 
grades. 
Metformin hydrochloride+ HPMC K4M+ HPMC E-5 
Metformin hydrochloride+ HPMC K4M+ HPMC E-15 
Metformin hydrochloride+ HPMC E-5+ HPMC E-15 
 Development of immediate release layer tablets: 
¾ Immediate release by using disintegrant 
i.e.,Glimepride+povidone 
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3. Optimization of sustained release formulae by optimizing variables and 
polymer concentration for the development of Bilayer tablet. 
4. Evaluation of formulation 
a) Precompression parameters 
¾ Bulk Density 
¾ Tapped Density 
¾ Angle of Repose 
¾ Carr’s Index 
¾ Hausner’s Ratio 
 
b) Physico-chemical characteristics of compressed Floating Bilayer tablets 
¾ Weight variation 
¾ Thickness  
¾ Hardness 
¾ Friability 
¾ Floating lag time 
¾ Total buoyancy time 
¾ Drug content analysis 
 
c) In-Vitro drug release 
¾ Tablet dissolution profile 
 
d) Comparison of Drug release kinetic profiles of different formulation. 
i.e., curve fitting analysis or kinetic model analysis 
 
5. Stability studies (as per ICH guidelines) 
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6. MATERIALS AND METHODS  
6.1 LIST OF MATERIALS 
Table No - 7 
List of Materials Used 
S.NO Materials Manufacturer 
1. Metformin hydrochloride Gift sample obtained from force India pharmaceuticals, Chennai. 
2. Glimepiride Gift sample obtained from force India pharmaceuticals, Chennai. 
3. HPMC K4M Hi Pure fine industries, Chennai   
4. HPMC E-5 Hi Pure fine industries, Chennai   
5. HPMC E-15 Hi Pure fine industries, Chennai   
6. Carbopol  Loba chemie Private Ltd,  Mumbai 
7. Sodium Bicarbonate  Nice chemicals Private Ltd, Kerala   
8. Citric Acid  Nice chemicals Private Ltd, Kerala   
9. Povidone  Nice chemicals Private Ltd, Chennai   
10. Di Calcium Phosphate   Nice chemicals Private Ltd, Kerala   
11 Magnesium stearate  Nice chemicals Private Ltd, Kerala   
12 Talc  Nice chemicals Private Ltd, Kerala   
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6.2 LIST OF EQUIPMENTS 
Table No – 8 
List of Equipments Used 
S.no Equipments Manufacturer Use 
1 
UV-Visible double beam 
spectrophotometer 
Shimadzu UV 
1700(Pharmaspec) 
To measure the 
absorbance of the sample 
2 Electronic Balance Sartorius Single Pan For weighing purpose 
3 
Rotary tablet punching 
machine 
Rimek MiniPress-I For tablet punching 
4 Friabilator Roche For friability testing 
5 Tablet Hardness tester Monsanto 
For testing hardness of 
the tablet 
6 
Programmable Dissolution 
test apparatus 
Electro Lab 
(Tablet Dissolution 
tester USP 24) 
For in-vitro dissolution 
studies 
7 pH meter Elico L 1120 
To measure the pH of the 
solution 
8. 
Environmental stability 
testing chamber 
Heco Environment 
Chamber 
For stability studies 
9. FT-IR 
Schimadzu IR – 
Prestige-21 
For compatibility 
analysis 
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6.3 PREPARATION OF REAGENTS 
6.3.1Preparation of 0.1N HCL 
 8.5 ml of Con.HCl dissolved in 1000ml of distilled water to prepare a 0.1N 
HCl. 
6.3.2 Stimulated Gastric Fluid pH 1.2 
0.2 gm sodium chloride and 0.7ml of concentrated hydrochloric acid were 
mixed, to this mixture 1000ml distilled water are added and the solution was 
adjusted to pH 1.2 with sodium hydroxide solution. 
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6.4 ABSORPTION MAXIMA AND STANDARD PLOTS 
6.4.1 Preparation of Absorption maxima for Metformin hydrochloride using 
pH 1.2 stimulated gastric fluid. 
 Accurately weighed amount of Metformin hydrochloride (100 mg) was 
dissolved in small quantity of stimulated gastric fluid pH 1.2 and then diluted to 
100 ml with the same solvent. Each ml of the stock solution contains 1 mg of 
Metformin hydrochloride. From this stock solution different standard of working 
standard solutions i.e., 10, 20, 30, 40, 50 µg/ml were made up with stimulated 
gastric fluid pH 1.2 and the absorbance was measured at 232nm using stimulated 
gastric fluid as blank by UV spectroscopic method47. A graph was plotted by 
using concentration at X-axis and absorbance at Y-axis. 
Absorption maxima and UV spectrum of Metformin hydrochloride 
 
 
Fig : 5 
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6.4.2 Standard Plot 
6.4.2.1 Standard plot of Metformin hydrochloride in stimulated gastric fluid 
pH 1.2 
Table No: 9 
Standard plot of Metformin HCl 
 
 
S.No 
 
Concentration µg/ml 
 
Absorbance at 232nm 
1                   0                   0 
2                  10              0.2897 
3                  20              0.5371 
4                  30              0.8484 
5                  40              1.118 
6                  50              1.39 
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Standard plot of Metformin hydrochloride in stimulated gastric fluid pH1.2 
 
 
 
Fig : 6 
 
6.4.3 Preparation of Absorption maxima for Glimepiride using pH 1.2 
stimulated gastric fluid. 
 Accurately weighed amount of Glimepiride (100 mg) was dissolved in 
small quantity of acetonitrile and then diluted to 100 ml with stimulated gastric 
fluid pH 1.2. Each ml of the stock solution contains 1 mg of Glimepiride. From 
this stock solution different standard of working standard solutions i.e., 10, 20, 30, 
40, 50 µg/ml were made up with stimulated gastric fluid pH 1.2 and the 
absorbance was measured at 226.7nm using stimulated gastric fluid as blank by 
UV spectroscopic method53. A graph was plotted by using concentration at X-axis 
and absorbance at Y-axis. 
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Absorption maxima and UV Spectrum of Glimepride  
 
 
 
Fig : 7 
Standard Plot 
6.4.4 Standard plot of Glimepiride in stimulated gastric fluid pH 1.2 
 
Table No : 10 
Standard curve of Glimepiride 
 
S.No Concentration µg/ml Absorbance at 226.7nm 
1 0 0 
2 10 0.231 
3 20 0.469 
4 30 0.700 
5 40 0.941 
6 50 1.145 
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Standard plot of Glimepiride in stimulated gastric fluid pH1.2 
 
 
 
Fig : 8 
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7. PREFORMULATION STUDIES 
Preformulation may be described as a stage of development process during 
which the researches characterize the physical, chemical and mechanical 
properties of the drug substance to form effective, stable and safe dosage form. 
Hence, Preformulation studies are essential to characterize the drug for proper 
designing of the drug delivery system. The Preformulation studies that were 
performing in this project include, 
 Description 
 Drug – excipient compatibility studies 
 Assay 
 
7.1 Description 
Organoleptic characters of drug was observed and recorded by using 
descriptive terminology. 
7.2Drug-Excipient Compatibility Studies by FT-IR Analysis 
Infrared spectrum of any compound or drug gives information about the 
groups present in that particular compound. The IR absorption spectra of the pure 
drug and physical admixtures of drug with various excipients were taken in the 
range of 4000-400 cm-1 using KBr disc method (Schimadzu IR- Prestige-21) and 
observed for characteristic peaks of drug. 
7.3 Assay  
A. For Metformin hydrochloride 
 Weigh accurately a quantity of the powder containing about 0.1g of 
Metformin hydrochloride, shake with 70ml of water for 15 minutes, make up to 
100ml with water, and filter. Dilute 10ml of the filtrate to 100ml with water. 
Further 10ml of the filtrate were make up to 100ml with water and measure the 
absorbance of the resulting solution at the maximum about 232nm. Calculate the 
content of C4H11N5, HCl taking 798 as the specific absorbance at 232nm. 
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  B. For Glimepiride 
  Twenty tablets from each batch were weighed and powdered. 
Powder equivalent to 4mg of Glimepiride was accurately weighed and transferred 
into 100ml volumetric flask and dissolve in acetronitrile until clear solution is 
obtained. The resulting solutions was made to 100ml with 0.1N HCl and shake for 
10 mins. The 10ml of the above solution was diluted up to 100ml with 0.1N HCl 
and flitered through 0.45µ membrane fliter analyzed by Shimadzu UV/VIS double 
beam spectrometer at 226.7nm. 
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8. FORMULATION & EVALUATION  
8.1 Formulation Development 
The pharmaceutical development studies have to be carried out with the 
purpose of selecting right dosage form and a stable formulation. These studies 
give detailed description of all the steps involved in the process development of 
Bilayer Floating tablet. Such details are intended towards identifying critical 
parameters involved in the process, which have to be controlled in order to give 
reliable and reproducible quality product. 
8.1.1 Formulation of floating Bilayer Tablet 
The floating Bilayer tablet was prepared by direct compression method. 
Steps involved in Bilayer Tablet Preparation 
1. Filling of immediate release layer of Glimepiride granules in to dies 
2. Slightly compressed the immediate release layer of Glimepiride granules 
3. Ejection of upper punch 
4. Addition of floating sustained release  layer of Metformin hydrochloride 
granules over the immediate release granules 
5. Increasing the compression force and compressed both the layer 
6. Ejection of floating Bilayer tablet  
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A. Preparation of Floating Metformin HCl Sustained Release (SR) 
Drug (Metformin hydrochloride) + Polymer (HPMC K4M, HPMC E-5, 
HPMC E-15) 
 
Gas generating agents (Sodium bicarbonate + citric acid) + Carbopol + Povidone 
 
Dry granules were passed through a mesh no: 44 
 
Mixed with magnesium stearate, talc 
 
Compression 
 
 
B. Preparation of Glimepiride Immediate Release (IR)] 
 
Drug (Glimepiride) + Povidone 
 
Dicalcium Phosphate (filler) + coloring agent 
 
Dry granules were passed through a mesh no: 44 
 
Mixed with magnesium stearate, talc 
 
Compression 
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  8.1.2 Consideration for Formulation Development 
) Formulation Development of Floating sustained release layer 
(MetforminHCl) by optimizing polymer concentration 
) Optimization of immediate release layer (Glimepiride) by variables. 
) Formulation of   floating Bilayer tablet from optimized formula on the 
basis of     in-vitro studies. 
8.1.3 Trial Formulations 
 Different formulation trial batches of Floating Metformin HCl SR and 
Glimepiride IR were formulated and studied for their release profiles to get the 
optimized formulation of Floating Bilayer tablet. 
8.1.3.1Formulation Trial Batch of Floating Metformin HCl SR Tablet  
 The trial batch of Floating Metformin HCl SR was prepared by employing 
drug with varying the percentage of polymers like HPMC E-15, HPMC E-5, 
HPMC K4M.  It was shown in the table (11). Different percentage of polymers 
have been used in trial batch and studied to have Metformin HCl sustaining effect 
for period of 20 hours. 
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Table No - 11 
 Formulation Trial Batch of Floating Metformin HCl SR (HPMC E-15) 
S.No Ingredients Formulation code (amount per tablet in mg) 
M1 M2 M3 M4 
1 Metformin HCL 250 250 250 250 
2 Polymer 
concentration (%) 
20 40 60 80 
3 HPMC E-15 50 100 150 200 
4 Carbopol 934 100 100 100 100 
5 Sodium bicarbonate 100 100 100 100 
6 Citric acid 50 50 50 50 
7 Povidone 50 50 50 50 
 
    Table No - 12 
Formulation Trial Batch of Floating Metformin HCl SR (HPMC E-5) 
S.No Ingredients Formulation code (amount per tablet in mg) 
M5 M6 M7 M8 
1 Metformin HCL 250 250 250 250 
2 Polymer 
concentration (%) 
20 40 60 80 
3 HPMC E-5 50 100 150 200 
4 Carbopol 934 100 100 100 100 
5 Sodium bicarbonate 100 100 100 100 
6 Citric acid 50 50 50 50 
7 Povidone 50 50 50 50 
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    Table No - 13 
Formulation Trial Batch of Floating Metformin HCl SR (HPMC K4M) 
S.No Ingredients Formulation code (amount per tablet in mg) 
M9 M10 M11 M12 
1 Metformin HCL 250 250 250 250 
2 Polymer 
concentration (%) 
20 40 60 80 
3 HPMC K4M 50 100 150 200 
4 Carbopol 934 100 100 100 100 
5 Sodium bicarbonate 100 100 100 100 
6 Citric acid 50 50 50 50 
7 Povidone 50 50 50 50 
Weight of active ingredient = 250mg 
Total weight of the tablet = 600mg 
 
8.1.3.2 Formulation Trial Batch of Glimepiride Immediate Release (IR) 
Tablet  
 The trial batch of Glimepiride IR tablet containing drug Glimepiride with 
disintegrant was prepared according to the following formula. Different 
percentage of disintegrant has been used in trial batch and to study the immediate 
release effect of Glimepiride. It was shown in the following table (14). 
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Table No - 14 
  Formulation Trial Batch of Glimepiride IR  
 
Ingredients 
Formulation code (amount per tablet in mg) 
G1 G2 G3 G4 
Glimepiride 1 1 1 1 
Povidone 4 6 8 10 
Dicalcium phosphate 38.98 38.98 38.98 38.98 
Magnesium stearate 1% 1% 1% 1% 
Talc 1% 1% 1% 1% 
   
Weight of active ingredient = 1mg 
Total weight of active ingredient = 50mg 
8.1.3.3Formulation of Floating Bilayer tablet of Metformin HCl SR and 
Glimepiride IR 
 From the trial formulations of Floating Metformin HCl SR and 
Glimepiride IR, the Bilayer floating tablet of Metformin HCl SR and Glimepiride 
IR are formulated by varying the percentage of polymers. 
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Table No – 15 
Percentage of polymer used  
Formulation code Percentage of polymer 
C1,C4,C7 20&60% 
C2,C5,C8 40&40% 
C3,C6,C9 60&20% 
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Table No - 16 
Formulation of Floating Bilayer tablet of Metformin HCl SR and 
Glimepiride IR 
S.No 
 
Ingredients Formulation code (amount per tablet in mg) 
C1 C2 C3 C4 C5 C6 C7 C8 C9 
1 Metformin HCl 250 250 250 250 250 250 250 250 250 
2 HPMC K4M 50 100 150 - - - 150 100 50 
3 HPMC E-15 150 100 50 50 100 150 - - - 
4 HPMC E-5 - - - 150 100 50 50 100 150 
5 Carbopol 934 100 100 100 100 100 100 100 100 100 
6 Sodium 
Bicarbonate 
100 100 100 100 100 100 100 100 100 
7 Citric Acid 50 50 50 50 50 50 50 50 50 
8 Povidone 60 60 60 60 60 60 60 60 60 
9 Glimepiride 1 1 1 1 1 1 1 1 1 
10 Povidone 10 10 10 10 10 10 10 10 10 
11 Dicalcium 
Phosphate 
38.9 38.9 38.9 38.9 38.9 38.9 38.9 38.9 38.9 
12 Magnesium 
Stearate 
1% 1% 1% 1% 1% 1% 1% 1% 1% 
13 Talc 1% 1% 1% 1% 1% 1% 1% 1% 1% 
 
Weight of active ingredient = 250mg 
Total weight of tablet = 650mg 
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8.2 EVALUATION PARAMETER 
Trial batches of different formulations of individual tablets (sustained and 
immediate) and Bilayer tablets were prepared and evaluated for the following 
parameters. 
Evaluation of granules 
 Bulk Density 
 Tapped Density 
 Angle of Repose 
 Carr’s Index 
 Hausner’s Ratio 
Physical evaluation of tablet 
 Weight variation 
 Thickness  
 Hardness 
 Friability 
 Swelling index 
 Floating lag time 
 Total buoyancy time 
 Drug content analysis 
 
 In-Vitro drug release study 
 Tablet dissolution profile 
[ 
Stability studies (As per ICH guidelines) 
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8.2.1 Evaluation of Granules51 
The ideal characteristics of a tablet that makes it a popular and acceptable 
dosage forms when they are compactness, physical stability, rapid production 
capability, chemical stability and efficacy. Many formulation and process 
variables involved in the granulation step can affect the characteristics of the 
granules. Therefore various granulation characteristics such as flow property, 
compressibility index have been measured to monitor the granulation stability. 
8.2.1.1Angle of repose 
 The angle of repose is defined as the maximum angle possible between the 
surface of a pile powder and the horizontal plane. The tangent of the angle is equal 
to the coefficient of friction between the particles. 
                         tanθ = h/r 
                                                    θ = tan-1 h/r 
                                       Where, h = height of the pile 
      r = radius of the pile. 
Procedure 
A funnel is fixed at particular height ‘h’ cm on a burette stand. A white 
paper is placed below the funnel on the table. The given powdered drug whose 
angle is to be determined is passed slowly through the funnel, until it forms a pile, 
care is taken to see that the drug particulars slip and roll over each other through 
the sides of the funnel. Circumference of the pile of drug is drawn with a pencil 
and the height of the pile was measured without disturbing the pile. The radius of 
the pile is noted down as ‘r’ cm. Angle of repose of the drug is then calculated by 
using the formulae. Standard value for flow property was shown in the table 
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     Table No - 17 
FLOW PROPERTIES AND CORRESPONDING ANGLE OF REPOSE  
Flow Property Angle of Repose (°) 
Excellent 25-30 
Good 31-35 
Fair – aid not needed 36 – 40 
Passable – may hang up 41 – 45 
Poor – mast agitate, vibrate 46 – 55 
Very poor 56 – 65 
Very, very poor >66 
 
8.2.1.2Bulk Density and Tapped Density 
A measured quantity of granules was transferred to a measuring cylinder 
measuring its initial volume [V0] and tapped mechanically either manually or 
using some tapping device till a constant volume [Vf] and it includes the true 
volume of the granules and void space between them. The bulk density and tapped 
density was calculated by the following formulae. Bulk density is the ratio 
between a mass of granules and its bulk volume (Vo).  It is expressed by g/cc. 
 
Bulk Density        = 
 
 
 
Mass of Powder 
Bulk Volume of Powder (Vo) 
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Tapped density is the ratio between mass of granules and volume of the 
granules after tapping (VF).  It is expressed by gm/cc. 
 
Tapped Density  = 
 
8.2.1.3Compressibility Index and Hausner’s Ratio 
The compressibility index and Hausner’s ratio are measures the flow 
property of a powder to be compressed. As such, they measure the relative 
importance as interparticulate Interactions. In a free flowing powder, such 
interactions are generally less significant and the bulk and tapped densities will be 
closer in values.  For poorer flowing materials, Inter particulate Interactions will 
be greater and greater difference between the bulk and tapped densities will be 
observed. These differences are reflected in the compressibility index and the 
Hausner’s ratio. 
The compressibility index and Hausner’s ratio are calculated by measuring 
the values for bulk density (ρ bulk) and Tapped Density (ρ tapped) as follows, and 
official limits are shown in the table(). 
 
Compressibility Index                 = 
 
 
 
 
 
Mass of Powder 
     Tapped Volume of Powder (VF) 
  Tapped density – Bulk density 
                                          X 100 
                Tapped density 
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    Table No - 18 
Official Limits for Carr’s Index 
Carr’s Index Types of flow 
5-15 Excellent 
12-16 Good 
18-23 Fair to pass 
23-35 Poor 
33-38 Very Poor 
Above Extremely Poor 
 
Hausner’s ratio is the measurement of frictional resistance of the drug and 
the ideal range should be 1.2-1.5 and the official limits are shown in table (). 
         Tapped Density 
          Hausner’s Ratio = 
                                               Bulk Density 
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Table No - 19 
Flow Properties and Corresponding Hausner’s Ratio 
Hausner’s Ratio Types of flow 
1-1.11 Excellent 
1.12-1.18 Good 
1.18-1.25 Fair 
1.26-1.34 Passable 
1.36-1.45 Poor 
1.46-1.59 Very Poor 
Above 1.6 Very Very Poor 
 
8.2Physical Evaluation of Tablet47 
8.2.1Weight variation 
Twenty tablets were randomly selected from each batch and individually 
weighed. The average weight and standard deviation of 20 tablets were calculated. 
The batch passes the test for weight variation test if not more than two of the 
individual weight deviates from the average weight by more than the percentage 
shown in the  table no(20) and none should deviate by more than twice the 
percentage shown. The average weight and standard deviation of the tablets of 
each batch were given in the table. 
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Table no - 20 
Weight Variation Specification (IP Limits) 
 
Average weight of tablet (mg) Percentage deviation 
80 or less 10 
80 to 250 7.5 
More than 250 5 
 
8.2.2Hardness 
 
The tablet-crushing load is the force required to break a tablet by 
compression. Hardness was measured by using hardness tester (Pfizer hardness 
tester). For each batch, six tablets were selected randomly and evaluated. 
Hardness of about 4-6 kg/cm2 is considered to be minimum for uncoated tablets 
and for mechanical stability. 
 
8.2.3Friability 
 
Friability test is performed to assess the effect of friction and shocks, 
which may often cause tablet to chip, cap or break.  Roche friabilator was used for 
the purpose.  Preweighed sample of ten tablets were placed in the friabilator, 
which was then operated for 100 revolutions. After 100 revolutions, the tablets 
were dusted and reweighed. Compressed tablets should not lose more than 1% of 
their weight. 
                                          Initial Weight – Final Weight 
 Percentage Friability =        X 100 
                                                    Final Weight 
8.2.4 Floating Lag Time 
 The tablets were placed in a 100ml beaker containing 0.1N HCl. The time 
required for the tablet to rise to the surface and float was determined as floating 
lag time. 
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8.2.5 Total Buoyancy Time 
 The time for which the tablets constantly float on the surface was 
determined as total buoyancy time. 
8.2.6 Swelling Index 
 Swelling of tablet excipients (polymer) involves the absorption of a liquid 
resulting in an increase in weight and volume. Liquid uptake by the particle may 
be due to saturation of capillary spaces within the particles or hydration of 
macromolecule. The liquid enters the particles through pores and bind to large 
molecule; breaking the hydrogen bond and resulting in the swelling of particle. 
The extent of swelling can be measured in terms of percentage weight gain by the 
tablet. 
Method    
 One tablet was weighed and placed in a beaker containing 200ml of 
distilled water. After each hour the tablet was removed from beaker and weighed 
again up to 5hrs. The %weight gain by the tablet was calculated by the formula,  
Swelling index (S.I)   =  {(Wt-W0)/W0}*100 
Where Wt    =  weight of tablet at time t, 
W0     =  weight of tablet before immersion. 
8.2.7 Drug content analysis 
For Metformin hydrochloride 
 Weigh accurately a Metformin hydrochloride, shake with 70ml of water 
for 15 minutes, make up to 100ml with water, and filter. Dilute 10ml of the filtrate 
to 100ml with water. Further 10ml of the filtrate were make up to 100ml with 
water and measure the absorbance of the resulting solution at the maximum about 
232nm. Calculate the content of C4H11N5, HCl taking 798 as the specific 
absorbance at 232nm. 
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For Glimepiride 
 Twenty tablets from each batch were weighed and powdered. Powder 
equivalent to 4mg of Glimepiride was accurately weighed and transferred into 
100ml volumetric flask and dissolve in acetronitrile until clear solution is 
obtained. The resulting solutions was made to 100ml with 0.1N HCl and shake for 
10 mins. The 10ml of the above solution was diluted up to 100ml with 0.1N HCl 
and flitered through 0.45µ membrane fliter analyzed by Shimadzu UV/VIS double 
beam spectrometer at 226.7nm. 
Percentage purity of  
Drug content  = Amount of drug       
            Label claim 
 
          
Amount of Drug    =        
 
 
 
Sample Weight  =                                                                                                                           
 
 
 
8.2.5 In-Vitro Drug Dissolution Test47 
 
The in-vitro dissolution study of Floating Metformin HCl SR tablet, 
Glimepiride IR tablet and optimized Bilayer Floating tablet of  Metformin HCl SR  
and Glimepiride IR were performed according to USP apparatus II (Basket type). 
The following parameters are considered for the dissolution study. 
 
 
  Sample OD                 Sample Dilution                                           
                   x                                 x Average Weight 
  A (1% 1cm)                Sample Weight     
        Average weight  
                      x  Equivalent weight  
         Label claim 
X 100 
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Table No - 21 
Parameters for In-Vitro Dissolution Study 
Parameters 
Metformin HCl 
floating sustained 
release tablet 
Glimepiride 
immediate Release 
Tablet 
Bilayer  Tablet of 
Floating Metformin 
HCl SR & 
Glimepiride IR 
Dissolution 
medium 
Stimulated Gastric 
fluid pH1.2 
Stimulated Gastric 
fluid pH1.2 
Stimulated Gastric 
fluid pH1.2 
Volume 900 ml 900 ml 900 ml 
Rpm 50 50 50 
Temperature 37º C ± 1º C 37º C ± 1º C 37º C ± 1º C 
UV 
Absorbance 
Measurement 
232 nm 226.7 nm 
Simultaneously at 
232 and 226.7 nm 
 
The dissolution study was carried out for all the formulations and the best 
release profiles were compared using kinetic model  
8.2.6Drug release kinetics52 
Several theories and kinetic models describe the dissolution of drug from 
immediate release and modified release dosage forms. There are several models to 
represent the drug dissolution profiles where f (t) is a function of time related to 
the amount of drug dissolved from the pharmaceutical dosage form. 
                The quantitative interpretation of the values obtained in the dissolution 
assay is facilitated by the usage of a generic equation that mathematically 
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translates the dissolution curve function of some parameters related with the 
pharmaceutical dosage forms. Drug dissolution from solid dosage forms has been 
described by kinetic models in which the dissolved amount of drug (Q) is a 
function of the test time‘t’ or Q(t). Some analytical definitions of the Q(t) function 
are commonly used, such as zero order, first order, Higuchi, Korsmeyer-Peppas, 
Hixson-Crowell models. These models are used to characterize drug 
dissolution/release profiles. 
(i) Zero Order Kinetics53 
This model represents an ideal release profile in order to achieve the 
pharmacological prolonged action. Zero order release constitutes drug release 
from the dosage form that is independent of the amount of drug in the delivery 
system (that is, a constant release rate). The following equation is used to express 
the model: 
Qt = Qo + Kot 
 
Where, Qt is the amount of drug dissolved in time t 
Qo is the initial amount of drug in the solution 
                                    Ko is the zero order release constant 
 
For practical purposes the equation is rearranged: 
Percent drug released = Kt 
 
This is applicable to dosage forms like transdermal systems, coated dosage 
forms, osmotic systems as well as matrix tablets with low soluble drugs. 
 
(ii) First Order Kinetics54 
 
First order release constitutes drug release in a way that is proportional to 
the amount of drug remaining in its interior; in such a way that amount of drug 
released by unit time diminish. The following equation is used to express the 
model: 
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log Qt = log Qo + Kt/2.303 
Where, Qt is the amount of drug dissolved in time t 
 
 Qo is the initial amount of drug in the solution 
                          K is the first order release constant 
For practical purposes the equation is rearranged: 
 
Log % of drug unreleased = Kt/2.303 
 
This model is applicable to dosage forms such as those containing water-
soluble drugs in porous matrices. 
 
(iii) Higuchi Model55 
 
Higuchi describes drug release as a diffusion process based in Fick’s law, 
square root dependent. The following equation is used to express the model: 
 
Qt = Kht1/2 
 
Where, Qt is the amount of drug dissolved in time t 
Kh is the first order release constant 
For practical purposes the equation is rearranged: 
 
Percent drug released = Kt1/2 
 
This model is applicable to systems with drug dispersed in uniform 
swellable polymer matrix as in case of matrix tablets with water soluble drugs. 
 
(iv) Peppas-Korsmeyer Model56 
 
This model is widely used when the release mechanism is not well known 
or when more than one type of release phenomenon could be involved 
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The following equation is used to express the model 
 
           Qt/Q∞ = Ktn 
 
Where, Qt is the amount of drug dissolved in time t 
 
                       Q∞ is the amount of drug dissolved in infinite time 
n is the release exponent indicative of drug release mechanism 
K is the kinetic constant 
 
For practical purposes the equation is rearranged: 
 
Log percent drug released = log k +n log t 
 
Peppas used n value in order to characterize different release mechanism 
concluding for values of n = 0.5 for Fickian diffusion and values of n, between 0.5 
to 1.0 for anomalous transport (corresponds to diffusion, erosion and swelling 
mechanism or mixed order kinetics) and higher values of n, n=1 or n>1 for case-II 
transport (corresponds to erosion and relaxation of swollen polymer layer). 
8.2.7 Stability Study57,58 
Stability is officially defined as the time lapse during which the drug 
product retains the same properties and characteristics that is possessed at the time 
of manufactures.  This process begins at early development phases.  Instabilities in 
modern formulation are often detected only after considerable storage periods 
under normal conditions.  To reduce their time required to obtain information’s, 
various tests that involve storage of products under condition that accelerate 
decomposition have been introduced. Stability storage condition shown in the 
table no(22). 
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 ICH Guidelines – Specifications 
 
 5% potency loss from initial assay of batch 
 Any specified degradation that exceed specifications 
 Product failing out of pharmacopoeial limits. 
 Dissolution out of specification for 12 minutes. 
 Failure to meet specification for appearance and physical properties. 
Any one condition is observed then stability of the batch is failed. 
Table No: 22 
STABILITY STORAGE CONDITIONS 
 
S.No. Study Period Storage Condition Minimum Duration 
1 Longer 25 + 2o C 60 + 5% RH 6 Months 
2 Intermediate 30 + 2 o C 60 + 5% RH 3 Months 
3 Accelerated 40 + 2o C 75 + 5% RH 3 Months 
 
The optimized bilayer floating tablets were packed in HDPE (high density 
poly ethylene) containers and kept in stability chamber at 40 o C/75% RH. After 
specific period of storage for stability, the tablets were evaluated for physical 
parameters, in-vitro drug release and assay. 
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9 RESULTS AND DISCUSSION 
9.1 Preformulation studies 
9.1.1 Description 
 Metformin hydrochloride : White to off white crystalline powder 
 Glimepiride      :  White crystalline powder  
 
9.1.2 Drug- Excipient Compatibility Studies by FT-IR analysis 
 
 Drug-Excipient compatibility was carried out by FT-IR analysis. Initially 
the IR spectrum of pure drug, Metformin HCl and Glimepiride and excipients like 
HPMC K4M, HPMC E-5 and HPMC E-15 was obtained. After that various 
admixtures of drug with other excipients like Metformin HCl, Glimepiride, 
HPMC K4M, HPMC E-5 and HPMC E-15 were prepared and IR spectra were 
obtained. The obtained spectra of physical admixtures were observed for major 
peaks and recorded.       
 In Metformin HCl drug was noticed that C-N stretching at 3303.04 and C-
H stretching at 2692.21 In Glimepiride drug was noticed that C-N stretching at 
3370.34 and C-H stretching at 2856.80. In combination of both the drugs 
(Metformin HCl & Glimepiride) C-N stretching at 3289.10, C-H  stretching at 
2856.80 and C-H(out of plane)  at 798.49. Functional group are more or less 
similar to that of individual pure drug. 
 In Metformin HCl was noticed that C-H stretching at 3171.90 and in 
Glimepiride drug was noticed that C-H aliphatic stretching at 2358.90. In 
combination of Metformin HCl , Glimepiride and Polymer were admixture 
and followed the same group in C-H stretching at 2939.64, 2944.65, 2940.92 and 
C-H aliphatic stretching at 2213.68, 2497.21, 2202.74. Functional group value are 
more or less similar that of individual pure drug.        
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 In Metformin HCl was noticed that N-H stretching at 3376.04 and in 
Glimepiride drug was noticed that C=S stretching at 1445.72 In combination of 
Metformin HCl , Glimepiride and Polymer were admixture and followed the 
same group in N-H stretching at 3375.06,3385.45,3383.44 C=S stretching 
at1442.18, 1446.64,1451.54. Functional group value are more or less similar that 
of individual pure drug. 
          In Metformin HCl was noticed that C-H out of plane at 931.65 and in 
Glimepiride drug was noticed that S=O stretching at 1347.41. In combination of 
Metformin HCl , Glimepiride and Polymer were admixture and followed the 
same group in C-H out of plane at 936.80, 939.58,937 S=O stretching at 1351.27. 
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FTIR SPECTRUM
ACIC
St.Joseph's  College ( Autonomous )
Trichy-2
Spectrum Name: GLIMEPRIDE.sp 
Date: 11/30/2011
GLIMEPRIDE.pk
GLIMEP~1.SP  1801  4000.00  400.00  6.02  99.99  4.00  %T  10  0.50
REF 4000 97.82 2000 91.61 600
3927.30  94.96  3791.72  90.66  3370.34  26.13  3289.10  28.00  3134.86  38.19  
2939.25  14.43  2856.80  19.70  2358.90  79.28  1933.21  89.13  1692.87  6.01   
1542.82  6.44   1445.72  20.36  1347.41  16.31  1282.45  18.77  1160.05  22.19  
1088.07  39.50  874.55   59.94  781.74   54.13  692.34   50.45  607.90   16.93  
434.93   89.62  
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3927.30
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434.93
 
Fig : 9 IR Spectral assignment of Glimepiride 
 
Table No : 23  
IR Spectral assignment of Glimepiride  
 
S.No Wave number(cm-1) Assignment 
1 3370.34 N-H stretching 
2 2939.25 C-H stretching(Aromatic) 
3 2358.90 C-H stretching(Aliphatic) 
4 1692.87 C=O stretching 
5 1445.72 C=N stretching 
6 1347.41 S=O stretching 
7 1282.45 C-N stretching 
8 1160.05 C=C stretching 
9 874.55 C-H outplane bending 
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FTIR SPECTRUM
ACIC
St.Joseph's  College ( Autonomous )
Trichy-2
Spectrum Name: Metformin.sp 
Date: 11/30/2011
Metformin.pk
METFOR~1.SP  1801  4000.00  400.00  3.58  90.75  4.00  %T  10  0.50
REF 4000 86.63 2000 80.79 600
3933.93  80.39  3796.80  82.13  3708.90  82.42  3376.04  4.76   3303.64  5.53   
3171.90  3.60   2692.21  24.59  2210.61  53.09  1575.83  3.58   1468.31  8.00   
1175.76  21.77  1055.77  17.84  931.65   34.17  798.49   76.49  637.77   25.17  
540.32   27.58  
4000.0 3000 2000 1500 1000 400.0
0.0
10
20
30
40
50
60
70
80
90
100.0
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3933.93
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Fig : 10 IR Spectral assignment of  Metformin HCl 
 
Table No : 24 
IR Spectral assignment of  Metformin HCl 
    
S.no Wavenumber (cm-1) Assignment 
1 3173.06 N-H stretching 
2 2687.10 C-H stretching 
3 1629.52 C=O stretching 
4 1573.03 C-N stretching 
5 1168.15 C-C stretching 
6 931.12 C-H out plane bending 
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FTIR SPECTRUM
ACIC
St.Joseph's  College ( Autonomous )
Trichy-2
Spectrum Name: HPMC E-5.sp 
Date: 11/30/2011
HPMC E-5.pk
HPMCE-~1.SP  1800  4000.00  402.00  3.77  164.32  4.00  %T  10  0.50
REF 4000 99.51 2000 56.99 600
3939.63  92.94   3787.33  87.64   3409.65  23.64   2916.15  18.27   2400.73  63.15   
2077.56  51.54   1641.82  25.48   1377.17  11.16   1058.73  3.77    601.89   37.60   
4000.0 3000 2000 1500 1000 402.0
0.0
10
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80
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100.0
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3787.33
3409.65
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Fig :  11 IR Spectral assignment of HPMC E-5 
 
  
Table No : 25 
IR Spectral assignment of HPMC E-5 
 
S.No Wavenumber (cm-1) Assignment 
1 3409.65 O-H stretching (primary amine) 
2 2916.15 C-H stretching 
3 2077.56 C-H stretching (Aliphatic) 
4 1641.82 C=O stretching (Isomeric carbonyl) 
5 1377.17 C-O bend 
6 1058.73 C-C bend 
7 601.89 C-H out of plane 
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FTIR SPECTRUM
ACIC
St.Joseph's College ( Autonomous )
Trichy-2
Spectrum Name: HPMC K4M.sp 
Date: 11/30/2011
HPMC K4M.pk
HPMCK4~1.SP  1800  4000.00  402.00  25.11  100.00  4.00  %T  10  0.50
REF 4000 67.47 2000 49.90 600
3921.53  63.57   3788.09  57.45   3384.40  25.11   3285.86  26.09   2938.73  25.33   
2133.37  46.26   1652.01  44.31   1371.83  37.99   1065.60  30.23   623.40   53.01   
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Fig :  12 IR Spectral assignment of HPMC K-4M 
 
Table No : 26 
IR Spectral assignment of HPMC K-4M 
 
S.No Wave number (cm-1) Assignment 
1 3409.65 O-H stretching (primary amine) 
2 2916.15 C-H stretching 
3 2077.56 C-H stretching (Aliphatic) 
4 1641.82 C=O stretching (Isomeric carbonyl) 
5 1377.17 C-O bend 
6 1058.73 C-C bend 
7 601.89 C-H out of plane 
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FTIR SPECTRUM
ACIC
St.Joseph's College ( Autonomous )
Trichy-2
Spectrum Name: Metformin+Glimepride+HPMC K4M.sp 
Date: 11/30/2011
Metformin+Glimepride+HPMC K4M.pk
METFOR~3.SP  1801  4000.00  400.00  4.89  100.00  4.00  %T  10  0.50
REF 4000 97.36 2000 94.82 600
3938.12  94.07   3839.82  94.81   3375.06  12.88   3296.88  15.71   3167.52  17.26   
2939.64  14.49   2202.74  81.71   1685.78  7.77    1546.64  4.88    1450.19  9.95    
1351.27  11.56   1280.61  15.57   1161.21  12.78   1068.13  16.64   939.58   41.55   
790.41   82.82   613.84   20.42   
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Fig :  13 IR Spectral assignment of physical mixture -I 
 
Table No : 27 
IR Spectral assignment of physical mixture –I 
(Metformin HCl+Glimepiride+HPMCK4M) 
 
S.No Wave number (cm-1) Assignment 
1 3276.88 N-H stretching 
2 3167.52 O-H stretching 
3 2939.64 C-H stretching 
4 1685.78 C=O stretching 
5 1450.19 C=N stretching 
6 1351.27 C=C stretching 
7 931.12 C-H out plane bending 
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Fig :  14 IR Spectral assignment of physical mixture –II 
 
Table No : 28 
IR Spectral assignment of physical mixture –II 
(Metformin HCl+Glimepiride+HPMCE-5) 
  
S.No Wavenumber (cm-1) Assignment 
1 3294.93 N-H stretching 
2 3157.52 O-H stretching 
3 2944.64 C-H stretching 
4 1442.18 C=N stretching 
5 1354.98 C=C stretching 
6 1065.36 C-N bend 
7 936.80 C-H out of plane 
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FTIR SPECTRUM
ACIC
St.Joseph's College ( Autonomous )
Trichy-2
Spectrum Name: Metformin+Glimepride+HPMC E15.sp 
Date: 11/30/2011
Metformin+Glimepride+HPMC E15.pk
METFOR~4.SP  1801  4000.00  400.00  3.19  99.52  4.00  %T  10  0.50
REF 4000 92.88 2000 84.62 600
3943.37  80.93  3383.44  3.24   3294.45  5.07   3193.86  6.65   2940.92  6.97   
2703.76  26.27  2497.21  44.98  2288.08  58.55  2200.18  57.10  1563.84  5.73   
1451.54  3.19   1356.88  5.18   1281.51  7.79   1161.82  5.95   1051.16  5.48   
937.00   17.58  792.94   79.37  610.18   12.31  
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Fig :  15 IR Spectral assignment of physical mixture –III 
 
Table No : 29 
IR Spectral assignment of physical mixture –III 
(Metformin HCl+Glimepiride+HPMCE-15) 
  
S.No Wavenumber (cm-1) Assignment 
1 3294.93 N-H stretching 
2 3157.52 O-H stretching 
3 2944.64 C-H stretching 
4 1442.18 C=N stretching 
5 1354.98 C=C stretching 
6 1065.36 C-N bend 
7 936.80 C-H out of plane 
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FTIR SPECTRUM
ACIC
St.Joseph's College ( Autonomous )
Trichy-2
Spectrum Name: Metformin+Glimepride+HPMC E15.sp 
Date: 11/30/2011
Metformin+Glimepride+HPMC E15.pk
METFOR~4.SP  1801  4000.00  400.00  3.19  99.52  4.00  %T  10  0.50
REF 4000 92.88 2000 84.62 600
3943.37  80.93  3383.44  3.24   3294.45  5.07   3193.86  6.65   2940.92  6.97   
2703.76  26.27  2497.21  44.98  2288.08  58.55  2200.18  57.10  1563.84  5.73   
1451.54  3.19   1356.88  5.18   1281.51  7.79   1161.82  5.95   1051.16  5.48   
937.00   17.58  792.94   79.37  610.18   12.31  
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Fig :  16 IR Spectral assignment of physical mixture –IV 
 
Table No : 30 
IR Spectral assignment of physical mixture –IV 
(Metformin HCl+Glimepiride+HPMCE-15) 
  
S.No Wavenumber (cm-1) Assignment 
1 3294.93 N-H stretching 
2 3157.52 O-H stretching 
3 2944.64 C-H stretching 
4 1442.18 C=N stretching 
5 1354.98 C=C stretching 
6 1065.36 C-N bend 
7 936.80 C-H out of plane 
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9.2 EVALUATION PARAMETER 
9.2.1 Evaluation of granules of Floating Metformin HCl SR 
  The prepared granules were subjected to Pre-Compression parameters and 
the values are found to be within limits (Carr’s index< 15% indicate excellent 
compressibility, Angle of repose<25° and Hausner’s ratio<1.25 indicates good 
flow property). The results of granules were shown in the table no (31). 
Table No : 31 
Precompression parameters of Floating Metformin HCl SR 
 
Formulation 
batch code 
Angle of 
repose (°)   
± S.D 
Bulk 
density 
(gm)  ± 
S.D 
Tapped 
density   
(gm)  ± 
S.D 
Carr’s 
Index    
(%) ± S.D 
Hausner’s 
Ratio ± 
S.D 
M4 23.98±0.3 0.49±0.05 0.59±0.01 14.82±0.56 1.02±0.4 
M8 24.34±0.2 0.54±0.03 0.61±0.03 13.92±0.67 1.04±0.3 
M12 26.59±0.4 0.56±0.02 0.62±0.02 15.01±0.28 1.11±0.6 
S.D = Standard Deviation, n=3 
 
9.2.1.2 Physical Evaluation of Floating Metformin HCl SR tablet  
All the formulated tablets of trial batch (M4,M8&M12) would lies within 
the Pharmacopoecial limits. The uniformity of weight lies between 0.640-0.690g, 
friability (0.3-0.5%), drug content (98.98-99.99%), hardness (4-6Kg/cm2) and 
Floating lag time was found to be 29,28&25secs. The 29and 28secs of M4&M8 
formulation indicates that the low viscosity grade polymer HPMCE-15 shows 
maximum floating lag time and 25secs of M12 indicates the high viscosity 
polymerHPMCK4M shows minimum floating lag time. The values are tabulated 
in the following table no(32).    
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Table No: 32 
Physico – Chemical Characteristics of Floating Metformin HCl SR 
 
Formulation 
batch code 
Average 
weight of 
tablets(g) 
± S.D 
Hardness 
(Kg/cm2) ± 
S.D 
Friability 
(%) ± S.D 
Drug 
content (%) 
± S.D 
Floating 
lag time 
(Secs) 
Total 
buoyancy 
time 
(Hrs) 
M4 0.651 ±0.014 4.2±0.2 0.29±0.06 98.26±0.41 29±0.01 20 
M8 0.649±0.022 4.8±0.1 0.3±0.04 98.99±0.52 28±0.23 20 
M12 0.650±0.011 4.1±0.3 0.2±0.01 99.99±0.12 25±0.12 20 
S.D = Standard Deviation, n=3 
 
Table No:33 
Determination of Swelling index for  Floating Metformin HCl SR 
 
Time (hrs) Formulation code 
M4 M8 M12 
1 50.83±0.5 56.55±0.2 65.50±0.26 
2 52.44±0.4 68.74±0.7 86.75±0.75 
3 61.12±0.1 78.56±0.6 97.82±0.28 
4 79.03±0.3 90.52±0.5 109.89±0.9 
5 95.23±0.26 105.23±0.3 128.55±0.5 
 
The formulation M12 shows the higher swelling index this is due to the 
viscosity of the polymer had major effect on swelling process. From the above, it 
was clear that swelling of tablet with increase in time passes because the polymer 
gradually absorbed water due to hydrophilic in nature and swell, the water 
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absorption rate increases as the viscosity of the polymer increases. At the end, the 
polymer of the higher viscosity shows the maximum absorption. It was shown in 
above table no(33). 
 
Fig : 17 
Determination of Swelling index for Floating Metformin HCl SR 
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9.2.1.3 In vitro drug release profile 
 The in vitro drug release study was carried out by using USP dissolution 
apparatus II (paddle type) and results were tabulated in the table (34). 
Table No: 34 
In vitro drug release of  Floating Metformin HCl SR 
 
 
 
 
 
 
Time (hrs) Cumulative % of drug released (±S.D) 
M4 M8 M12 
0 0 0 0 
0.25 4.31±0.31 5.07±0.73 6.59±0.52 
0.5 9.66±0.60 9.15±0.12 14.55±0.58 
1 13.54±0.54 13.01±0.14 18.59±0.54 
2 18.85±0.86 17.82±0.86 27.96±0.94 
4 24.15±0.12 22.46±0.42 33.11±0.19 
6 30.57±0.56 27.28±0.29 41.24±0.26 
8 37.99±0.98 31.03±0.34 47.13±0.14 
10 43.31±0.31 36.17±0.13 53.98±0.96 
12 48.92±0.99 40.98±0.92 61.18±0.12 
14 53.68±0.67 49.69±0.63 67.24±0.24 
16 61.79±0.75 54.33±0.34 75.67±0.64 
18 66.09±0.96 60.78±0.76 83.24±0.23 
20 70.8±0.82 66.19±0.18 86.12±0.19 
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Fig : 18 
In vitro drug release profile of Floating Metformin HCl SR 
 
 
 
From the in vitro profile for  Floating Metformin HCl SR (M4,M8&M12) 
the drug released was found to be 70.8%,66.19% & 86.12% respectively at the 
end of 20hrs. From this release profile, it was evident that the formulation M12 
was suitable and it is suitable for SR formulation. (The formulation M4 &M8 did 
not follow the USP limit for SR i.e.,NLT 80%released at 20hrs)    
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9.2.2 Evaluation of Glimepiride immediate release tablet; 
9.2.2.1Evaluation of granules 
The results of precompression parameters for different formulation batches of 
Glimepiride immediate release tablet were shown in the table no(35). 
Table no:35 
 Precompression Parameters of Glimepiride immediate release layer 
Trial Batch G1 to G4 
Formulation 
batch code 
Angle of 
Repose (o) 
± S.D 
Bulk 
Density 
(g/ml) ± 
S.D 
Tapped 
Density 
(g/ml) ± 
S.D 
Carr’s Index 
(%) 
± S.D 
Hausner’s 
Ratio ± S.D
G1 29.71 ± 0.319 0.21 ± 0.01 0.23 ± 0.01 10.43 ± 0.31 1.09 ± 0.01 
G2 28.19 ± 0.101 0.19 ± 0.04 0.21 ± 0.03 9.91 ± 0.08 1.11 ± 0.01 
G3 29.48 ± 0.268 0.20 ± 0.02 0.22 ± 0.02 10.47 ± 0.29 1.11 ± 0.01 
G4 25.33 ± 0.136 0.21 ± 0.02 0.24 ± 0.01 9.66 ± 0.85 1.08 ± 0.02 
S. D = Standard Deviation, n=3 
 
The prepared granules were subjected to Pre-Compression parameters and the 
values are found to be within limits (Carr’s index< 15% indicate excellent 
compressibility, Angle of repose<25° and Hausner’s ratio<1.25 indicates good 
flow property). The results of granules were shown in the table no (35). 
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9.2.2.2Physical Evaluation of Glimepiride IR Tablets 
The results of physico-chemical characterization of different formulation 
batches of Glimepiride IR tablet were summarized in the table no (36). The results 
shows that the formulation G1-G4 lies within IP limits weight variation, Hardness, 
Friability and Drug content. 
 
Table no:36 
 Physico – Chemical Characteristics of Glimepiride immediate release layer 
Tablets  
Trial Batch G1 to G4 
Formulation 
batch code 
Average 
weight of 
tablets(g) 
± S.D 
Hardness 
(Kg/cm2) ± 
S.D 
Friability 
(%) ± S.D 
Drug content 
(%) 
± S.D 
G1 0.49 ± 0.006 5.2 ± 0.1 0.43 ± 0.01 99.15 ± 1.27 
G2 0.48 ± 0.004 5.7 ± 0.2 0.44 ± 0.05 98.07 ± 0.56 
G3 0.49 ± 0.009 5.1 ± 0.1 0.38 ± 0.03 99.26 ± 0.45 
G4 0.51 ± 0.006 5.5 ± 0.4 0.51 ± 0.03 99.97 ± 1.05 
S. D = Standard Deviation, n=3 
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9.2.2.3In-Vitro Drug Release Profile 
 The in vitro drug release study was carried out by using USP dissolution 
apparatus II (paddle type) and results were tabulated in the table (37). 
 
Table no : 37 
 Dissolution Profile of Formulation Trail Batch G1 to G4 
 
Time(Hrs) Formulation batch code 
G1 G2 G3 G4 
0 0 0 0 0 
0.5 12.25±0.45 18.17±0.17 29.27±0,25 33.97±0.79 
1 26.78±0.7 36.15±0.5 52.71±0.7 65.37±0.31 
2 48.59±0.5 55.78±0.8 77.97±0.73 84.13±0.26 
3 64.78±0.8 70.83±0.34 89.34±0.34 99.95±0.91 
4 79.32±0.23 81.67±0.45 92.49±0.49 - 
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Fig : 19 Invitro Profile of Immediate release (G1-G4) 
 
  
 
From the in vitro profile for formulation G1-G4 the drug released was 
found to be 64.78%, 70.83%, 89.34% & 99.95% at the end of 3 hrs. From the 
release profile G4 was suitable for IR formulation. 
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9.2.3 Evaluation of Floating Bilayer tablet of Metformin HCl SR & 
Glimepiride IR 
The results of precompression parameters for different formulation batches 
of Floating Bilayer tablet of Metformin HCl SR & Glimepiride IR tablet were 
shown in the table no(35). 
 
Table no: 38 
Precompression Parameters of Floating Bilayer tablet of Metformin HCl SR 
and Glimepiride IR 
Formulation 
batch code 
Angle of 
repose (°)    
± S.D 
Bulk 
density 
(gm)  ± 
S.D 
Tapped 
density   
(gm)  ± 
S.D 
Carr’s 
Index    
(%) ± S.D 
Hausner’s 
Ratio ± 
S.D 
C1 25.65±0.02 0.52±0.02 0.49±0.02 13.93±0.3 1.11±0.02 
C2 26.93±0.3 0.54±0.04 0.54±0.34 14.92±0.5 1.19±0.1 
C3 28.45±0.2 0.56±0.21 0.58±0.43 14.98±0.2 1.05±0.01 
C4 24.78±0.08 0.51±0.31 0.52±0.02 12.93±0.02 1.12±0.03 
C5 23.24±0.03 0.58±0.81 0.51±0.04 14.82±0.08 1.18±0.02 
C6 23.67±0.34 0.49±0.09 0.59±0.03 15.92±0.72 1.12±0.2 
C7 24.73±0.34 0.52±0.01 0.62±0.06 14.92±0.04 1.13±0.1 
C8 23.94±0.02 0.56±0.2 0.68±0.34 13.92±0.05 1.16±0.4 
C9 22.82±0.4 0.58±0.02 0.64±0.56 14.02±0.4 1.15±0.5 
S.D = Standard Deviation, n=3 
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9.2.3.1 Physico – Chemical Characteristics of Floating Bilayer tablet of 
Metformin HCl SR & Glimepiride IR 
 The results of physico-chemical characterization of different 
formulation batches of  Floating Bilayer tablet were summarized in the table no 
(39). The results shows that the formulation C1-C9 lies within IP limits weight 
variation, Hardness, Friability and Drug content. 
     Table no:39 
Physico – Chemical Characteristics of Floating Bilayer tablet of Metformin 
HCl SR and Glimepiride IR 
 
Formulation 
batch code 
Average 
weight of 
tablets(g) 
± S.D 
Hardness 
(Kg/cm2) ± 
S.D 
Friability 
(%) ± S.D 
Drug 
content (%)
± S.D 
Floating 
lag time 
(Secs) 
Total 
buoyancy 
time 
(Hrs) 
C1 0.650±0.23 4.4±0.8 0.2±.02 97.98±0.25 25±0.2 19±.12 
C2 0.649±0.22 4.8±0.6 0.3±0.04 98.99±0.52 26±0.23 20±0.34 
C3 0.651±0.23 4.8±0.82 0.2±0.01 99.99±0.9 25±.18 20±0.24 
C4 0.651 ±0.14 4.2±0.2 0.29±0.06 98.26±0.41 28±0.01 21±0.56 
C5 0.654±0.23 5.32±0.3 0.3±0.01 96.99±0.6 27±0.85 20±0.9 
C6 0.650±0.11 5.1±0.5 0.2±0.02 99.99±0.12 30±0.12 21±0.2 
C7 0.654±0.42 5.2±0.12 0.26±0.03 97.67±0.23 32±0.45 21±0.1 
C8 0.652±0.2 4.4±.12 0.24±0.01 98.23±0.45 29±0.38 22±0.8 
C9 0.653±0.3 4.2±.9 0.04±0.12 97.34±0.56 30±0.64 24±.9 
S.D = Standard Deviation, n=3 
The floating lag time and total buoyancy time for formulation C3 was shown in 
the fig (20) 
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Fig : 20 
Floating  Lag time of formulation  C3 
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Fig : 20 
Floating  Lag time of formulation  C3 
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Fig : 20 
Floating  Lag time of formulation  C3 
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Fig : 20 
Floating  Lag time of formulation  C3 
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Fig : 20 
Floating  Lag time of formulation  C3 
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Table no: 40 
Determination of Swelling index for Floating Bilayer tablet of Metformin HCl SR and Glimepiride IR 
 
Time 
(hrs) 
Formulation code 
C1 C2 C3 C4 C5 C6 C7 C8 C9 
1 64.56±0.6 65.50±0.5 91.21±0.2 50.83±0.8 55.23±0.3 56.55±0.5 62.89±0.8 30.55±0.5 32.72±0.7 
2 67.83±0.8 86.75±0.7 98.50±0.6 52.44±0.4 62.51±0.5 68.74±0.7 72.44±0.4 31.65±0.6 38.45±0.4 
3 103.88±0.8 97.82±0.8 118.40±0.4 61.12±0.1 70.34±0.4 91.85±0.8 96.35±0.3 33.80±0.8 46.61±0.6 
4 119.66±0.6 128.55±0.5 155.90±0.9 79.03±0.3 82.12±0.2 105.25±0.5 110.29±0.5 47.33±0.3 51.12±0.1 
5 125.12±0.1 141.47±0.5 168.49±0.4 95.58±0.5 90.53±0.5 107.42±0.4 125.58±0.7 48.28±0.9 60.67±0.6 
 
The swelling index of formulation C3,C6 &C7 shows the maximum of about 168.49,107.42 &125.58.From the results it was found that C3 
formulation was found to have maximum swelling index due to combination of high viscosity polymers. It was shown in the fig. (21) 
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Fig: 21 
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Table no: 41 
Dissolution study of Floating Bilayer tablet of Metformin HCl SR and Glimepiride IR 
Time 
in 
hours 
Cumulative % of drug released (±S.D) 
C1 C2 C3 C4 C5 C6 C7 C8 C9 
0 0 0 0 0 0 0 0 0 0 
0.25 4.9±0.21 5.25±0.54 10.35±0.2 4.52±0.23 6.65±0.23 8.99±0.45 10.58±0.3 9.69±0.1 8.76±0.9 
0.5 8.18±0.5 9.27±0.2 18.19±0.8 7.99±0.3 11.64±0.5 13.66±0.4 16.44±0.6 14.11±0.3 16.55±0.4 
1 11.93±0.8 13.67±0.4 24.69±0.9 10.07±0.7 20.54±0.5 21.99±0.9 21.78±0.7 19.24±0.9 24.82±0.3 
2 16.47±0.4 18.34±0.3 27.95±0.9 13.86±0.8 24.15±0.1 26.07±0.7 29.71±0.7 26.87±0.8 29.32±0.3 
4 22.17±0.1 24.42±0.2 36.25±0.2 19.02±0.1 3.7±0.7 33.78±0.7 36.04±0.4 32.71±0.1 35.04±0.4 
6 30.69±0.6 32.92±0.9 40.52±0.5 24.28±0.2 38.58±0.5 39.96±0.9 44.81±0.8 39.67±0.6 39.73±0.7 
8 35.89±0.8 35.27±0.2 47.24±0.2 29.32±0.3 44.4±0.4 45.87±0.8 51.43±0.4 48.59±0.5 45.11±0.1 
10 39.74±0.7 40.52±0.5 58.34±0.3 37.98±0.9 49. 81±0.6 56.08±0.8 59.60±0.6 54.35±0.3 52.61±0.6 
12 47.74±0.7 49.42±0.4 68.37±0.3 45.54±0.5 52.68±0.6 64.66±0.6 64.42±0.4 59.66±0.6 59.83±0.8 
14 56.12±0.1 56.85±0.2 76.05±0.5 56.42±0.4 59.46±0.4 69.71±0.7 70.25±0.2 62.11±0.1 63.11±0.1 
16 63.96±0.9 58.94±0.9 85.24±0.2 61.07±0.7 65.96±0.9 76.42±0.4 78.35±0.3 69.54±0.5 69.76±0.7 
18 70.35±0.3 65.31±0.3 92.52±0.5 66.85±0.8 70.68±0.6 82.20±0.2 87.38±0.3 74.79±0.7 73.75±0.7 
20 78.96±0.1 79.96±0.9 101.92±0.1 72.73±0.7 76.61±0.6 88.47±0.4 92.25±0.2 79.47±0.4 78.98±0.9 
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Fig : 22 in vitro release profile of floating bilayer tablet. 
 
 
 
The formulation C3, C6&C9 the drug released was found to be 
101.92%,88.47%&92.25% From the dissolution profile the formulation C1-C9 it 
was clearly shown that the formulation C3,C6 and C7 are suitable for SR 
formulation and it complies the USP limits.(NLT 80% released at 20hrs).  
This is due to combination of low viscosity and high viscosity polymer. 
For C3 the percentage of polymer is 60&20% (HPMC K4M & HPMC E-15), C6 
the percentage of polymer is 60&20% (HPMC E-15& HPMC E-5) and C7 the 
percentage of polymer is 20&60% (HPMC E-5& HPMC K4M). 
 From the formulation C3,C6 and C7 the formulation C3 was found to 
suitable for SR formulation, this is because the release of drug was retarded by 
employing the high viscosity polymer (HPMCK4M) when compared to low 
viscosity polymers HPMC E-15 and HPMC E-5. 
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Drug release kinetic models 
 
Formulation (C3) 
Fig : 23 Zero order plot  
 
 
 
Fig : 24 First order plot  
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Fig : 25  Higuchi  Model  
 
 
 
Fig : 26  Peppas Model  
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Drug release kinetic models 
 
Formulation (C6) 
 
Fig : 27 Zero order plot  
 
Fig : 28 First order plot  
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Fig : 29  Higuchi  Model  
 
 
 
Fig : 30  Peppas Model  
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Drug release kinetic models 
 
Formulation (C7) 
Fig : 31 Zero order plot  
 
 
Fig : 32 First order plot  
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Fig : 33  Higuchi  Model  
 
 
 
Fig : 34  Peppas Model  
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Table – 42 
 
Descriptive Statistics of Regression and Parameters of the Mathematical 
Models for the Dissolution Data of floating Bilayer tablet of Metformin HCl 
SR & Glimepiride IR  
 
 
Kinetic 
models 
Statistical 
parameter C3 C6 C7 
Zero-Order 
R2
m 
K 
0.990 
4.276 
16.13 
0.879 
3.765 
15.06 
0.956 
3.956 
16.08 
First-Order 
R2
m 
K 
0.794 
0.090 
-0.086 
0.801 
0.080 
-0.028 
0.794 
0.09 
-0.081 
Higuchi 
R2
m 
K 
0.958 
21.17 
-2.454 
0.885 
19.0 
-1.125 
0.908 
20.10 
-1.998 
Peppas 
R2 
n 
K 
0.966 
0.596 
1.328 
0.786 
0.08 
-0.094 
0.932 
0.43 
0.9 
 
 The results of  dissolution data of optimized floating bilayer tablet of 
Metformin HCl SR and Glimepiride IR formulation C3,C6 &C7were fitted to 
various drug release kinetic models i.e., Zero-Order, First Order, Higuchi and 
Peppas models to find out the relese mechanism of the drug. 
The calculated R2 and K values are shown in the table no(42). From the 
results it was concluded that all formulation follows zero-order than first order. It 
is acceptable for sustained release formulation to fit  in zero-order than in first-
order. 
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 From Peppas model, n value was used to describe the release mechanism 
of drug from sustained release dosage form. The diffusion co-efficient of ‘n’ value 
of peppas model    0.5-1 indicates the release of drug follows anamalous transport 
of Non-fickian diffusion. (corresponds to diffusion and erosion mechanism or 
mixed order kinetics) C3 formulation diffusion co-efficient ‘n’ value of peppas 
model 0.596 it follows within the limits. 
Stability study 
   The physico-chemical and in vitro release of floating Bilayer tablet kept at 
40ºC/75% RH were studied for 3 months as per ICH guidelines. The parameters 
are shown in the table (43). 
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Table - 43 
Stability study for Floating Bilayer tablet (C3) 
 
S.No Parameters Initial After 3 
months 
Acceptance 
criteria 
1 Description Complies Complies White color SR 
layer and pink color 
IR layer 
2 Average weight (mg) 649.8 648.9 640-660 
3 Friability (%) 0.2 0.19 Less than 1 
4 Hardness (Kg/cm2) 4.5 4.2 4-6 
5 Drug content (%) 
Metformin HCl 99.96 99.03 95%-105% 
Glimepiride 98.76 97.9 90%-110% 
6 Floating lag time 
(secs) 
25 24 25 
7 Total buoyancy time 
(hrs) 
20 20 20 
   
From the description, average weight, friability, hardness, drug content, 
floating lag time and total buoyancy time studies carried out after 3 months 
completion it was clear that the formulation C3 revealed no significant change 
from initial values which indicates the formulation was stable. 
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In vitro dissolution test 
 The physical, chemical and In vitro release of floating Bilayer tablet of 
Metformin HCl & Glimepiride tablets kept at 40ºC/75% RH were studied for 3 
months as per ICH guidelines. The in vitro release study was carried out by using 
USP dissolution apparatus II and results are shown in table (44). 
Table - 44 
Comparative In vitro Dissolution profile of floating Bilayer tablet of 
Metformin HCl & Glimepiride (C3). Before and after storage at                
40ºC/75% RH 
Time 
in 
hours 
Cumulative % of drug released (±S.D) 
Initial End of first 
month 
End of 
second 
month 
End of third 
month 
0 0 0 0 0 
0.25 10.5±0.2          10.5±0.2 10.35±0.2 9.95±0.2 
0.5 18.06±0.8 17.19±0.8 18.19±0.8 17.19±0.8 
1 23.69±0.9 24.69±0.9 24.69±0.9 23.69±0.9 
2 29.95±0.9 27.95±0.9 27.95±0.9 28.95±0.9 
4 35.25±0.2 36.25±0.2 36.25±0.2 35.25±0.2 
6 41.52±0.5 40.52±0.5 40.52±0.5 42.52±0.5 
8 48.24±0.2 47.24±0.2 47.24±0.2 48.24±0.2 
10 59.34±0.3 58.34±0.3 58.34±0.3 57.34±0.3 
12 68.37±0.3 68.37±0.3 68.37±0.3 69.37±0.3 
14 76.05±0.5 76.05±0.5 76.05±0.5 75.05±0.5 
16 89.24±0.2 85.24±0.2 85.24±0.2 88.24±0.2 
18 92.52±0.5 92.52±0.5 92.52±0.5 92.52±0.5 
20 100.92±0.1 100.02±0.5 99.99±0.2 98.86±0.3 
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 Fig : 35 Stability study of formulation C3 at the end of 3 months 
 
 
 
From the dissolution profile, the formulation C3 was selected for the 
stability studies. The cumulative % of drug release at zero month was 100.92% at 
20hrs. After first and third month completion the cumulative % of drug release 
was 100.02%,99.99% &98.86  at the end of 20hrs. The formulation C3 revealed 
that no significant change from initial values which indicates the formulation were 
stable. 
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SUMMARY AND CONCLUSION 
 
Floating Bilayer tablet of Metformin HCl SR and Glimepiride IR were 
formulated using HPMC K4M, HPMC E-15 and HPMC E-15 in alone (80%) and 
in combination of  different percentage of polymer (20&60%,40&40% and 
60&20%). 
Three different formulations (M4, M8 &M12 ) of floating Metformin HCl 
SR tablets are prepared by employing the hydrophilic polymer HPMC in different 
viscosity  grades in the percentage of 80%. From that M12 formulation were 
found to be suitable for formulating SR tablet by its in vitro release. From the 
M12 formulation, it was clear that when the polymer concentration increases it 
decreases the release rate. 
Formulations of C1-C9 of floating Bilayer tablets are prepared by 
combining the different viscosity polymers (HPMC K4M+HPMC E-15,                 
HPMC E-15+HPMC E-5 & HPMC E-5+HPMC K4M) in the percentage 0f 
20&60%,40&40% and 60&20% 
The formulation C3 (HPMC K4M[60%]+HPMC E-15[20%]),                          
C6 (HPMCE-5 [20%]+HPMCE-15[60%]) and C7  (HPMC K4M[60%] +                   
HPMC E-5[20%]) were found to suitable for formulating SR by its in vitro release 
studies and it show release about 101.92%, 88.47% and 92.25%. 
From the C3 formulation it was shown that the percentage of high 
viscosity polymer can be reduced by adding low viscosity polymer.  
From the dissolution profile of formulation C3 it was well understood that 
the release of drug from its formulation can be improved by combining the low 
and high viscosity polymers compared to formulating M12 high viscosity polymer 
alone. From this  study it was concluded that Floating time increases, it decreases  
the release rate. So it suitable for sustained release formulation.  
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